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TRAIL	  and	  cell	  death	  	  
1.1	  An	  overview	  on	  cellular	  apoptosis	  	  For	  a	  single-­‐cell	  organism,	  life	  with	  mutations	  is	  apparently	  better	  than	  no	  life	  at	  all,	  but	  in	   multicellular	   organisms	   the	   health	   of	   the	   organism	   takes	   precedence	   over	   the	   life	   of	   an	  individual	  cell	  and	  thus,	  when	  DNA	  damage	  occurs,	  the	  cells	  do	  not	  attempt	  to	  continue	  division	  but	   instead	   “commit	   suicide”	   by	   undergoing	   apoptosis.	   Apoptosis	   is	   a	   process	   leading	   to	   cell	  death,	  whereby	  unnecessary	  or	  damaged	  cells	  can	  be	  eliminated.	  According	  to	  the	  source	  of	  the	  pro-­‐apoptotic	   signal,	  which	   can	  be	   either	   intracellular	   or	   extracellular,	   two	   separate	  ways	   of	  signalling	   take	   place,	   both	   converging	   to	   the	   activation	   of	   effector	   caspases	   and	   ultimately	  leading	  to	  cell	  death.	  These	  two	  ways	  of	  signalling	  have	  been	  divided	  into	  the	  intrinsic	  pathway,	  triggered	  by	  an	  intracellular	  signal,	  such	  as	  DNA	  damage,	  and	  the	  extrinsic	  pathway,	  triggered	  by	  an	  extracellular	  signal,	  which	  usually	  derives	  from	  cytotoxic	  cells	  of	  the	  immune	  system,	  as	  in	  (Figure	  1)[Bernardi,	  2012a].	  	  Briefly,	   the	   activation	   of	   the	   intrinsic	   pathway	   depends	   on	   the	   balance	   between	  intracellular	   pro-­‐apoptotic	   and	   anti-­‐apoptotic	   proteins	   that	   control	   the	   release	   of	  mitochondrial	  cytochrome	  C,	  leading	  to	  the	  formation	  of	  the	  apoptosome,	  caspases	  activation,	  and	  then	  cell	  death	  (Figure	  1).	  The	  proteins	  regulating	  the	  intrinsic	  pathway	  belong	  to	  the	  Bcl-­‐2	  family	  and	  they	  can	  be	  further	  divided	  into	  different	  subfamilies	  based	  on	  their	  function	  and	  structure.	  Some	  of	  them	  (e.g.	  Bax,	  Bak,	  and	  Bok)	  stimulate	  the	  release	  of	  cytochrome	  C,	  whereas	  other	   members	   (e.g.	   Bcl-­‐2,	   Bcl-­‐xL,	   and	   MCL-­‐1)	   inhibit	   this	   process.	   A	   subfamily	   of	   these	  proteins	   is	   the	   BH3-­‐only	   group,	  whose	  members	   share	   only	   the	   BH3	   domain	  with	   the	   other	  proteins	  [Adams,	  2007].	  Bid	  is	  an	  important	  member	  of	  the	  BH3-­‐only	  group	  since	  it	  connects	  the	   apoptotic	   pathways	   by	   transmitting	   apoptotic	   signals	   from	   the	   extrinsic	   to	   the	   intrinsic	  pathway.	  When	  pro-­‐apoptotic	  molecules	  cause	  the	  permeabilization	  of	  the	  outer	  mitochondrial	  membrane,	   a	   protein	   called	   Smac/DIABLO	   is	   also	   released	   into	   the	   cytosol,	  which	   indirectly	  promotes	   apoptosis.	   Chai	   and	   colleagues	   have	   in	   fact	   demonstrated	   that	   the	   mitochondrial	  protein	   Smac/DIABLO	   interferes	   with	   the	   inhibitors	   of	   apoptosis	   proteins	   (IAP),	   thereby	  promoting	  the	  proteolytic	  activation	  of	  procaspase-­‐3	  [Chai,	  2000;	  Wu,	  2000].	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On	   the	   other	   hand,	   the	   activation	   of	   the	   extrinsic	   pathway	   depends	   on	   the	   binding	   of	  specific	  pro-­‐apoptotic	  ligands,	  such	  as	  FasL/CD95L,	  tumor	  necrosis	  factor-­‐α	  (TNF-­‐α)	  and	  TNF-­‐related	  apoptosis-­‐inducing	  ligand	  (TRAIL)	  to	  their	  transmembrane	  receptors	  (Figure	  1).	  This	  stimulates	   the	   trimerization	   of	   the	   transmembrane	   receptors	   and	   the	   recruitment	   of	   Fas	  associated	  death	  domain	  (FADD).	  Subsequently,	  FADD	  recruits	  both	  caspase-­‐8	  and	  caspase-­‐10,	  which	  undergo	  auto-­‐activation	  by	  proteolytic	  cleavage	  and	  in	  turn	  activate	  caspase-­‐3,	  caspase-­‐6,	   and	   caspase-­‐7,	   which	   execute	   the	   apoptotic	   program.	   In	   some	   cells,	   called	   type	   1,	   the	  extrinsic	  pathway	  generates	  a	  signal	  strong	  enough	  to	  initiate	  apoptosis	  by	  itself.	  However,	  in	  the	   majority	   of	   cells,	   called	   type	   2,	   this	   signal	   needs	   to	   be	   amplified	   to	   induce	   apoptosis	  [Ozoren,	   2002].	   This	   amplification	   can	   be	   generally	   achieved	   by	   a	   cross-­‐talk	   between	   the	  extrinsic	  and	  the	  intrinsic	  pathway.	  	  	  
	  
Figure	  1.	  Key	  components	  of	  the	  intrinsic	  and	  extrinsic	  apoptotic	  pathways	  Intrinsic	  pathway:	  DNA	  damage	  activates	  p53,	  which	  stimulates	  the	  intrinsic	  pathway	  by	  upregulating	  Puma	  and	  Noxa,	  which	  inhibit	  the	  anti-­‐apoptotic	  Bcl-­‐2,	  Bcl-­‐xL,	  and	  MCL-­‐1	  and	  thus	  activate	  the	  pro-­‐apoptotic	  Bax	  and	  Bak.	  Bax	  and	  Bak	  then	  stimulate	  the	  release	  of	  cythocrome	  C,	  which	  binds	  to	  the	  adaptor	  Apaf-­‐1	  to	  recruit	  the	  initiator	  procaspase-­‐9	  into	  a	  signalling	  complex	  termed	  apoptosome,	  which	  subsequently	  undergoes	  activation.	  Caspase-­‐9	  then	  generates	  caspase-­‐3,	  caspase-­‐6,	  and	  caspase-­‐7.	  In	   addition	   to	   the	   release	   of	   cytochrome	   C,	   the	   permeabilisation	   of	   the	  mithocondrial	  membrane	   causes	   the	   release	   of	   the	  protein	  Smac/DIABLO,	  which	  promotes	  apoptosis	  by	  blocking	  the	  inhibitor	  of	  apoptosis	  proteins	  (IAP),	  which	  normally	  inhibits	  the	  activity	  of	  several	  caspases.	  Extrinsic	  pathway:	   	   specific	  extracellular	  homotrimers	   interact	  selectively	  with	   their	  specific	  transmembrane	  death	  receptors.	  Ligand	  binding	  induces	  receptor	  clustering	  and	  recruitment	  of	  Fas-­‐associated	  death	  domain	  (FADD),	   procaspase-­‐8,	   and	  procaspase-­‐10,	  which	   then	  undergo	   activation	   and	   form	  altogether	   the	  death-­‐inducing	   signalling	  complex	  (DISC).	  This	  activates	  caspase-­‐3,	  caspase-­‐6,	  and	  caspase-­‐7,	  which	  then	  trigger	  apoptosis.	  In	  addition,	  caspase-­‐8	  cleaves	  Bid	  and	  truncated	  Bid	  subsequently	  stimulates	  Bax	  and	  Bak	  to	  activate	  the	  intrinsic	  pathway.	  Of	  note,	  DISC	  formation	  may	  be	  blocked	  by	  several	  mechanisms	  such	  as	  the	  presence	  of	  c-­‐FLIP.	  The	  cross-­‐talk	  between	  the	  extrinsic	  and	  the	  intrinsic	  pathways	  relies	  on	  Smac/DIABLO	  and	  truncated	  Bid.	  	  	  (Adapted	  from	  Bernardi,	  2012a)	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1.2	  TRAIL	  biology	  	  TRAIL	  is	  one	  of	  the	  proteins	  binding	  to	  the	  pro-­‐apoptotic	  transmembrane	  receptors,	  also	  called	  death	  receptors	  (DRs),	  which	  engage	  the	  extrinsic	  apoptotic	  pathway.	  TRAIL	  belongs	  to	  the	  TNF	  family	  of	  death-­‐inducing	  ligands	  and	  was	  cloned	  on	  the	  basis	  of	  its	  sequence	  homology	  to	  TNF-­‐α	  and	  FasL/CD95L	  [Wiley,	  1995].	  The	  percentage	  of	  identity	  with	  FasL/CD95L,	  TNF-­‐α,	  lymphotoxin	  (Lt)-­‐α,	  and	  Lt-­‐β,	  which	  are	  the	  most	  related	  members	  of	  the	  TNF	  family,	   is	  28%,	  23%,	  23%,	  and	  22%	  respectively.	  The	  gene	  encoding	  for	  TRAIL	  has	  been	  mapped	  to	  the	  3q26	  chromosomal	   region.	   It	   spans	   approximately	   20	   kb,	   and	   has	   five	   exons	   and	   four	   introns.	   In	  humans,	   TRAIL	   is	   expressed	   as	   a	   type	   II	   transmembrane	   protein	   of	   281	   amino	   acids,	  whose	  extracellular	   C-­‐terminal	   domain	   undergoes	   enzymatic	   cleavage.	   Subsequently,	   TRAIL	   is	  released	   as	   a	   soluble	  molecule	  with	   biological	   activity.	   The	   cysteine	   residue	   at	   position	   230	  (Cys230)	  allows	  TRAIL	  to	  interact	  and	  assemble	  with	  other	  two	  molecules	  of	  TRAIL	  forming	  a	  trimeric	  ligand.	  TRAIL	  homotrimers	  are	  one	  of	  the	  pro-­‐apoptotic	  receptor	  agonists	  that	  bind	  to	  DRs	  on	  the	  surface	  of	  target	  cells	  and	  induce	  apoptosis	  (Figure	  1)	  	  	  Five	  human	  receptors	  for	  TRAIL	  have	  been	  identified	  so	  far,	  which	  can	  be	  divided	  into	  death	  receptors	  (DRs)	  and	  decoy	  receptors	  (DcRs).	  DRs	  are	  TRAIL-­‐R1	  (DR4/TNFRSF10A)	  [Pan,	  
1997a]	   and	   TRAIL-­‐R2	   (DR5/TNFRSF10B)	   [Pan,	   1997b;	   Sheridan,	   1997;	  Wu,	   1997;	  Milani,	  
2003],	  which	  are	  both	  type	  I	  transmembrane	  proteins	  containing	  an	  intracellular	  death	  domain	  that	  classically	  stimulates	  apoptosis	  upon	  TRAIL	  binding.	  A	  major	  contribution	  of	  our	  group	  to	  the	   biology	   of	   the	   TRAIL/TRAIL-­‐R	   system	  was	   the	   discovery	   that	   when	   TRAIL-­‐R1/DR4	   and	  TRAIL-­‐R2/DR5	  are	  activated	  they	  not	  only	  stimulate	  the	  extrinsic	  apoptotic	  pathway,	  but	  they	  may	   also	   activate	   survival/proliferation	   pathways,	   such	   as	   nuclear	   factor	   kB	   (NF-­‐kB),	  ERK1/ERK2,	   and	   Akt	   [Harper,	   2001;	   Secchiero,	   2003;	   Zauli,	   2005].	   The	   second	   class	   of	  receptors	   includes	   the	   decoy	   receptors	   TRAIL-­‐R3	   (TRID/DcR1/TNFRSF10C)	   [Degli-­‐Esposti,	  
1997a],	   TRAIL-­‐R4	   (DcR2/TNFRSF10D)	   [Degli-­‐Esposti,	   1997b;	   Marsters,	   1997],	   and	  osteoprotegerin	  (OPG)	  [Zauli,	  2009].	  	  TRAIL	  is	  expressed	  on	  the	  surface	  of	  activated	  immune	  cells,	  such	  as	  natural	  killer	  (NK)	  cells,	   T	   cells,	   macrophages	   and	   dendritic	   cells,	   where	   it	   apparently	   functions	   as	   an	   immune	  effector	  molecule	  and	  it	  mediates	  anti-­‐tumor	  cytotoxicity	  and	  immune	  surveillance	  [Di	  Pietro,	  
2004;	   Secchiero,	   2008].	   Studies	   on	   TRAIL	   -­‐/-­‐	   mice	   have	   demonstrated	   that	   mice	   without	  TRAIL	  are	  viable	  and	  fertile	  but	  more	  susceptible	  to	  tumor	  metastases,	  indicating	  role	  of	  TRAIL	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in	   immune	   surveillance	   and	   host	   defence	   against	   tumor	   initiation	   and	   progression	   [Cretney,	  
2002;	   Sedger,	   2002].	   In	   particular,	   TRAIL	   seems	   to	  mediate	   the	   ability	   of	   NK	   cells	   to	   block	  tumor	   growth	   and	   metastases	   development	   as	   well	   as	   some	   abilities	   of	   memory	   T	   cells	  [Janssen,	  2005].	  	  	  One	   of	   the	   unique	   aspects	   of	   TRAIL	   is	   that	   it	   has	   the	   ability	   to	   induce	   apoptosis	  preferentially	  in	  tumor	  cells,	  while	  it	  spares	  most	  normal	  cells	  [Ashkenazi,	  2008a].	  The	  balance	  between	   TRAIL	   death	   and	   decoy	   receptors	   was	   initially	   considered	   a	   possible	   mechanism	  whereby	   cells	   could	   negatively	   regulate	   TRAIL-­‐induced	   cytotoxicity,	   therefore	   explaining	  TRAIL	   selectivity.	   Nevertheless,	   a	   correlation	   between	   this	   ratio	   and	   either	   protection	   or	  susceptibility	  to	  apoptosis	  has	  never	  been	  clearly	  demonstrated	  [Lincz,	  2001;	  Wuchter,	  2001;	  
Mirandola,	  2004;	  Kim,	  2000]	  and	  it	  is	  still	  under	  debate.	  	  	  
	  
1.3	  TNF-­‐family	  members	  targeting	  the	  extrinsic	  apoptotic	  pathway	  	  	  Agents	  that	  promote	  or	  restore	  apoptosis	  through	  the	  extrinsic	  pathway	  have	  emerged	  as	  a	  promising	  anti-­‐cancer	   therapeutic	   strategy.	   	  The	  vast	  majority	  of	  mechanisms	   leading	   to	  apoptosis	   resistance	   and	   non	   responsiveness	   to	   anti-­‐cancer	   agents	   involve	   the	   intrinsic	  apoptotic	   pathway,	   possibly	   because	   it	   has	   greater	   involvement	   in	   the	   initial	   elimination	   of	  oncogene-­‐transformed	   cells.	   These	  mechanisms	   include	  mutations	   related	   to	   p53,	  mutations	  modulating	  the	  ratio	  between	  pro-­‐apototic	  and	  anti-­‐apoptotic	  proteins,	  and/or	  overexpression	  of	  proteins	  belonging	  to	  the	  IAP	  family.	  So,	  agents	  that	  promote	  or	  restore	  apoptosis	  through	  the	  extrinsic	  pathway,	   such	  as	  pro-­‐apoptotic	   receptor	   agonists,	   should	  be	  able	   to	   circumvent	  some	   of	   the	   mutations	   leading	   to	   apoptosis	   resistance	   and	   therefore	   to	   overcome	   the	   non-­‐responsiveness	   of	   tumor	   cells	   to	   anti-­‐cancer	   therapies.	   For	   example,	   the	   activation	   of	   the	  extrinsic	   pathway	   induces	   apoptosis	   in	   tumors	   that	   are	   not	   responsive	   to	   chemotherapy	  because	  they	  have	  developed	  mutations	  of	  p53	  [Ravi,	  2004].	  An	  additional	  reason	  that	  makes	  pro-­‐apoptotic	  receptor	  agonists	  such	  an	  attractive	  therapeutic	  tool	  in	  the	  fight	  against	  cancer	  is	  that,	   given	   the	   interplay	   between	   intrinsic	   and	   extrinsic	   pathway,	   activating	   the	   extrinsic	  pathway	  may	  not	  only	   facilitate	   the	  outcome	  of	  conventional	  chemotherapies	  but	   it	  may	  also	  have	   a	   synergistic	   effect	   when	   combined	   to	   them	   (Figure	   1),	   as	   many	   studies	   have	  demonstrated	  [Nagata,	  1997].	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Experimental	  evidence,	  however,	  has	  shown	  that	  not	  all	  the	  extracellular	  pro-­‐apoptotic	  ligands	  could	  be	  used	  as	  anti-­‐cancer	  agents,	  given	  that	  some	  of	  them	  display	  a	   low	  selectivity	  for	   tumors	   compared	  with	  normal	   cells	   [Nagata,	  1997;	  Tartaglia,	  1992].	   For	   example,	   ever	  since	  the	  systemic	  delivery	  of	  Fas/Apo1/CD95	  resulted	  in	  acute,	   lethal	  hepatotoxicity	   in	  mice	  this	   agent	   has	   been	   dismissed	   for	   cancer	   therapy	   [Verbrugge,	   2009;	   Shiraishi,	   2004].	  Likewise,	   TNF-­‐α	   systemic	   delivery	   caused	   pulmonary	   failure	   and	   coagulopathies	   as	   well	   as	  other	   symptomatic	   toxicities	   such	   as	   chills,	   fever,	  malaise,	   headache,	  myalgia,	   and	   nausea	   or	  vomiting	  in	  13%	  of	  the	  patients	  studied.	  Therefore,	  these	  severe	  toxic	  effects	  that	  are	  elicited	  by	   FasL	   and	   TNF-­‐α	   have	   precluded	   both	   ligands	   from	   use	   as	   systemic	   anti-­‐cancer	   therapies	  [Nagata,	  1997;	  Tartaglia,	  1992].	  	  	  In	   contrast	   to	   FasL	   and	  TNF-­‐α,	   the	  pro-­‐apoptotic	   ligand	  TRAIL,	   also	   known	  as	  Apo2L,	  seems	   to	   preferentially	   induce	   apoptosis	   in	   tumor	   cells	   rather	   than	   in	   normal	   cells	   in	   vitro	  [Ashkenazi,	   1999].	   Consistent	  with	   this,	   preclinical	   safety	   trials	   have	  demonstrated	   that	   this	  ligand	   does	   not	   cause	   toxic	   effects	   even	   at	   high	   doses.	   In	   particular,	   in	   their	   seminal	   study,	  Ashkenazi	   and	   colleagues	   demonstrated	   that	   the	   exposure	   of	   cynomolgus	   monkeys	   to	  recombinant	   human	   (rh)-­‐TRAIL	   at	   0.1-­‐10	  mg/Kg/day	   over	   7	   days	   did	   not	   induce	   detectable	  toxicity,	   whereas	   for	   comparison,	   TNF-­‐α	   induced	   severe	   toxicity	   at	   0.003	   mg/Kg/day	  [Marsters,	  1997].	  On	  the	  basis	  of	  these	  properties,	  various	  agents/strategies	  targeting	  TRAIL-­‐R1/DR4	  and	  TRAIL-­‐R2/DR5	  have	  been	  developed.	  Most	   of	   these	  have	  been	   so	   far	   extremely	  well	  tolerated	  in	  clinical	  safety	  trial.	  These	  include:	  recombinant	  Apo2L/TRAIL,	  TRAIL-­‐R1/DR4	  and	  TRAIL-­‐R2/DR5	  monoclonal	  antibodies,	  collectively	  called	  pro-­‐apoptotic	  receptor	  agonists	  (PARAs),	   as	   well	   as	   TRAIL	   gene-­‐delivering	   strategies	   and	   small	   molecules	   binding	   to	   death	  receptors.	  	  Chronologically,	  the	  first	  of	  these	  molecules	  that	  had	  been	  developed	  were	  recombinant	  versions	  of	  the	  soluble	  Apo2L/TRAIL,	  including	  a	  non	  tagged	  protein	  and	  versions	  tagged	  with	  exogenous	   polypeptides	   to	   improve	   the	   stabilization	   of	   the	   homotrimeric	   structure,	   such	   as	  oligomeric	  TRAIL	  polypeptides	  joined	  through	  leucine	  zippers	  called	  LZ-­‐TRAIL	  [Wiley,	  2001].	  Ashkenazi	   and	   colleagues	   developed	   an	   optimized,	   clinical-­‐grade	   version	   of	   rh-­‐TRAIL,	  consisting	   of	   amino	   acids	   114-­‐281	   of	   the	   endogenous	   molecule,	   without	   any	   added	   tag	  [Ashkenazi,	   2000]	   and	   with	   only	   a	   zinc	   molecule	   located	   at	   position	   230	   of	   each	   subunit	  helping	   to	   stabilize	   the	   trimeric	   protein	   structure.	   Subsequently,	   several	   TRAIL-­‐R1/DR4	   and	  TRAIL-­‐R2/DR5	  monoclonal	   antibodies	   have	   been	   developed	   [Chuntarapai,	   2001;	   Ichikawa,	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2001;	  Georgakis,	  2005;	  Ashkenazi,	  2001;	  Salcedo,	  2003;	  Camellia,	  2006].	  Among	  these,	  LBY-­‐135	  is	  the	  only	  chimeric,	  rather	  than	  fully	  human,	  monoclonal	  antibody	  against	  TRAIL-­‐R2/DR5	  [Li,	   2008]	   (Table	   1).	   Although	   PARAs	   share	   the	   same	   mechanism	   of	   action,	   the	  pharmacological	   characteristics	   that	   they	   display	   are	   different	   and	   this	   may	   influence	   their	  therapeutic	   potential.	   For	   example,	   the	   serum	   half-­‐life	   of	   rh-­‐TRAIL	   is	   30	   to	   60	   minutes	   in	  humans,	  whereas	  the	  serum	  half-­‐life	  of	  the	  antibodies	  ranges	  from	  6	  to	  21	  days.	  In	  addition,	  rh-­‐TRAIL	   binds	   not	   only	   to	   TRAIL-­‐R1/DR4	   and	  TRAIL-­‐R2/DR5,	   like	   the	  monoclonal	   antibodies,	  but	  also	  to	  OPG,	  TRAIL-­‐R3/DcR1	  and	  TRAIL-­‐R4/DcR2	  [Wiezorek,	  2010].	  	  	  
Table	  1.	  Summary	  of	  the	  pro-­‐apoptotic	  receptor	  agonists	  	  	  
Molecule	   Developed	  by	   Mechanism/Pharmacology	  
Ad5-­‐TRAIL	   ___	   Recombinant	  adenovirus	  encoding	  human	  Apo2L/TRAIL	  AMG655	  	  Conatumumab	   Amgen	   Human	  mAb	  targeting	  DR5	  
Apomab	   Genentech	   Human	  mAb	  targeting	  DR5	  
CS-­‐1008/TRA8	  Tigatuzumab	   Daiichi	  Sankyo	   Humanized	  version	  (CS-­‐1008)	  of	  murine	  DR5-­‐targeting	  antibody	  (TRA-­‐8)	  HGS-­‐ETR1	  	  Mapatumumab	   HGS	  GSK	   Human	  mAb	  targeting	  DR4	  
HGS-­‐ETR2	  	  Lexatumumab	   HGS	   Human	  mAb	  targeting	  DR5	  
LBY135	   Novartis	   Chimeric	  mAb	  targeting	  DR5	  
PRO1762/AMG951	  Dulanermin	   Genentech/Amgen	   rhApo2L/TRAIL	  targeting	  DR4	  and	  DR5	  
PRO95780	   Genentech	   Human	  mAb	  targeting	  DR5	  
DRAs	   ___	   Small	  molecules	  activating	  DRs	  	  
Abbreviations:	  TRAIL,	  TNF-­‐related	  apoptosis-­‐inducing	  ligand;	  DRAs,	  death	  receptors	  agonists/activators;	  HGS,	  Human	  Genome	  Science;	   GSK,	   Glaxo	   Smith	   Kline;	   mAb,	   monoclonal	   antibody;	   DR4,	   death	   receptor	   4;	   DR5,	   death	   receptor	   5.	   (Adapted	   from	  
Bernardi,	  2012a).	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1.4	  Preclinical	  and	  clinical	  data	  on	  the	  effects	  of	  TRAIL	  and	  TRAIL	  agonists	  	  The	  first	  preclinical	  data	  for	  the	  soluble,	  non	  tagged	  rh-­‐TRAIL	  were	  published	  in	  1999	  by	  Ashkenazi	   and	   colleagues	   [Ashkenazi,	   1999],	   demonstrating	   that	   this	   molecule	   induced	  apoptosis	  in	  cell	  lines	  derived	  from	  human	  colon,	  lung,	  breast,	  central	  nervous	  system,	  kidney	  and	  skin	  cancer,	  while	  it	  spared	  normal	  cells.	  Following	  studies	  showed	  that	  rh-­‐TRAIL	  was	  able	  to	   induce	   apoptosis	   in	   other	   malignant	   cell	   lines	   derived	   from	   prostate	   cancer	   [Yu,	   2000],	  thyroid	  cancer	  [Mitsiades,	  2000],	  leukemia	  [Yao,	  2007],	  multiple	  myeloma	  [Mitsiades,	  2001]	  and	   non-­‐Hodgkin’s	   lymphoma	   (NHL)	   [Daniel,	   2007].	   Consistent	  with	   these	   data	   obtained	   in	  vitro,	  TRAIL	  displayed	  a	  marked	  anti-­‐tumor	  activity	  in	  vivo,	  in	  models	  of	  mouse	  xenografts	  of	  human	  colon	  or	  lung	  cancer,	  multiple	  myeloma,	  NHL,	  and	  glioma.	  Subsequently,	  the	  preclinical	  studies	   on	   the	   efficacy	   of	   TRAIL-­‐R1/DR4	   and	   TRAIL-­‐R2/DR5	   demonstrated	   that	   also	   these	  monoclonal	  antibodies	  were	  able	  to	  induce	  apoptosis	  in	  a	  wide	  variety	  of	  tumor	  cell	  lines	  and	  primary	  tumor	  explants	  [Ichikawa,	  2001;	  Ashkenazi,	  2008b].	  	  	  Based	  on	  these	  promising	  preclinical	  results,	  the	  safety	  and	  the	  efficacy	  of	  pro-­‐apoptotic	  receptor	  agonists	  have	  been	  evaluated	  in	  phase	  I	  and	  II	  clinical	  trials,	  as	  summarized	  in	  Table	  2	  [Herbst,	  2010a;	  Soria,	  2010;	  Tolcher,	  2007;	  Hotte,	  2008;	  Leong,	  2009;	  Mom,	  2009;	  Younes,	  
2010;	   Trarbach,	   2010;	   Greco,	   2008;	   Herbst,	   2010b;	   Doi,	   2011;	  Wakelee,	   2010;	   Plummer,	  
2007;	   Camidge,	   2010;	   Forero-­‐Torres,	   2010].	   Overall,	   these	   studies	   have	   demonstrated	   that	  the	  pro-­‐apoptotic	  receptor	  agonists	  are	  safe	  and	  well	  tolerated.	  These	  works	  have	  given	  ground	  for	  additional	   trials,	   some	  still	  ongoing	   [Ashkenazi,	  2008c].	  Focusing	  on	   rh-­‐TRAIL,	   two	  main	  trials	  have	  been	  conducted	  so	  far.	   In	  the	  first	  one,	  which	  was	  a	  phase	  I,	  open-­‐label,	  and	  dose-­‐escalation	  study,	  patients	  with	  advanced	  cancer	  were	  treated	  with	  rh-­‐TRAIL	  at	  a	  dose	  ranging	  from	   0.5	   to	   30mg/kg/day.	   Doses	   were	   given	   daily	   for	   5	   days,	   every	   3	   weeks.	   A	   total	   of	   71	  patients	   were	   treated,	   among	   whom	   only	   2	   drug-­‐related	   dose-­‐limiting	   adverse	   events	   were	  observed	  and	  a	  maximum	  tolerated	  dose	  was	  not	  reached	  during	  the	  dose	  escalation	  phase.	  In	  this	  study,	  rh-­‐TRAIL	  demonstrated	  linear	  pharmacokinetic,	  with	  an	  estimated	  effective	  half-­‐life	  of	   half	   an	  hour.	  Notably,	   one	  patient	  with	   chondrosarcoma	  exhibited	   a	  partial	   response	  with	  >80%	  tumor	  regression	  [Herbst,	  2010a].	  The	  second	  one	  was	  a	  phase	  Ib	  study	  in	  relapsed	  low-­‐grade	   NHL	   and	   non-­‐small-­‐cell	   lung	   carcinoma	   (NSCLC)	   [Soria,	   2010].	   In	   NSCLC,	   the	  combination	  of	  rh-­‐TRAIL	  with	  carboplatin,	  paclitaxel	  and	  bevacizumab	  showed	  a	  70%	  overall	  tumor	  response	  rate	  with	  1	  complete	  and	  13	  partial	  responses	  in	  the	  18	  patients	  treated.	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Table	  2.	  Development	  status	  of	  some	  of	  the	  pro-­‐apoptotic	  receptor	  agonists	  	  
Phase/Treatment	   Patients	   Results	  
Conatumumab:	   	   	  Phase	  Ia-­‐Monotherapy	   Advanced	  solid	  tumors	  (n=37)	   No	  DTL;	  no	  MTD	  up	  to	  20	  mg/kg	  Q2W;	  1	  PR	  in	  NSCLC	  Phase	  Ia-­‐Monotherapy	   Advanced	  solid	  tumors	  (n=18)	   No	  DTL;	  no	  MTD	  up	  to	  20	  mg/kg	  Q2W	  
Dulanermin:	   	   	  Phase	  Ia-­‐Monotherapy	   Advanced	  solid	  tumors	  or	  NHL	  (n=71)	   2	  DLTs;	  no	  MTD	  up	  to	  15mg/kg/d	  for	  5d	  Q3W;	  1	  PR	  in	  chondrosarcoma	  Phase	  Ib-­‐+PAC,	  CAR	  and	  BEV	   Stage	  IIIb/IV	  or	  recurrent	  NSCLC	  (n=24)	   No	  DLT;	  no	  MTD	  up	  to	  20	  mg/kg/d	  for	  2d	  Q3W;	  1	  CR;	  13	  PRs	  
Lexatumumab:	   	   	  Phase	  Ia-­‐Monotherapy	   Advanced	  solid	  tumors	  (n=37)	   3	  DTLs;	  MTD	  at	  10mg/kg	  Q3W;	  no	  objective	  responses	  Phase	  Ia-­‐Monotherapy	   Advanced	  solid	  tumors	  (n=31)	   1	  DTLs;	  no	  MTD	  at	  10mg/kg	  Q2W;	  no	  objectives	  responses	  
Mapatumumab:	   	   	  Phase	  Ia-­‐Monotherapy	   Advanced	  solid	  tumors	  (n=49)	   3	  DTLs;	  no	  MTD	  up	  to	  10	  mg/kg	  Q2W;	  no	  objective	  responses	  Phase	  Ia-­‐Monotherapy	   Advanced	  solid	  tumors	  (n=41)	   No	  DTL;	  no	  MTD	  up	  to	  20mg/kg	  Q4W;	  no	  objective	  responses	  Phase	  Ib-­‐+PAC	  and	  CAR	   Advanced	  solid	  tumors	  (n=27)	   2	  DTLs;	  no	  MTD	  up	  to	  20mg/kg	  Q3W;	  5	  PRs	  Phase	  Ib-­‐+GEM	  and	  CIS	   Advanced	  solid	  tumors	  (n=49)	   5	  DTLs;	  no	  MTD	  up	  to	  30mg/kg	  Q3W;	  12	  PRs	  Phase	  II-­‐Monotherary	   Relapsed/refractory	  NHL	  (n=40)	   No	  DTL;	  no	  MTD	  up	  to	  10mg/kg	  Q3W;	  2CRs	  1	  PR	  Phase	  II-­‐Monotherapy	   Relapsed/refrectory	  CRC	  (n=38)	   No	  DTLs;	  no	  MTD	  up	  to	  20mg/kg	  Q2W;	  no	  objective	  responses	  Phase	  II-­‐Monotherapy	   Relapsed/refractory	  NSCLC	  (n=32)	   No	  DTLs;	  no	  MTD	  up	  to	  10mg/kg	  Q3W;	  no	  objective	  responses	  
PRO95780:	   	   	  Phase	  Ia-­‐Monotherapy	   Advanced	  solid	  tumors	  or	  NHL	  (n=50)	   4	  DTLs;	  no	  MTD	  up	  to	  20mg/kg	  Q2W;	  no	  objective	  responses	  
Tigatuzumab:	   	   	  Phase	  Ia-­‐Monotherapy	   Relapsed/refractory	  solid	  tumors/NHL	  (n=17)	   No	  DTL;	  no	  MTD	  up	  to	  8mg/kg	  QW;	  no	  objectives	  responses	  Abbreviations:	   PAC,	   paclitaxel;	   CAR,	   carboplatin;	   BEV,	   bevacizumab;	   GEM,	   gemcitabine;	   CIS,	   cisplatin;	   NHL,	   non-­‐Hodgkin	  lymphoma;	  NSCLC,	  non-­‐small	   cell	   lung	   cancer;	  CRC,	   colorectal	   cancer;	  DLT,	  dose-­‐limiting	   toxicity;	  MTD,	  maximum	   tolerated	  dose;	  QW,	  once	  per	  week;	  Q2W,	  every	  2	  weeks;	  Q3W,	  every	  3	  weeks;	  Q4W,	  every	  4	  weeks;	  PR,	  partial	  response;	  CR,	  complete	  response.	  (Adapted	  from	  Bernardi,	  2012a)	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1.5	  rh-­‐TRAIL-­‐based	  combinational	  therapy	  	  A	  large	  number	  of	  studies	  have	  revealed	  that	  combining	  TRAIL	  with	  either	  traditional	  or	  novel	   anti-­‐cancer	   agents	  may	   reverse	   the	   resistance	   to	  monotherapy.	   Interestingly,	   it	   seems	  that	   low	   concentrations	   of	   chemotherapeutics	   can	   enhance	   the	   sensitivity	   to	   TRAIL	   or	   the	  TRAIL	  receptor	  antibody	  HGS-­‐ETR1	  by	  accumulating	  the	  TRAIL-­‐R1/DR4	  at	  the	  cell	  surface	  [Jin,	  
2007].	  On	  the	  other	  hand,	  pre-­‐treatment	  with	  chemotherapeutic	  agents	  of	  Bax-­‐/-­‐	  human	  colon	  cancer	  cells	  that	  are	  resistant	  to	  TRAIL	  has	  been	  shown	  to	  restore	  TRAIL	  sensitivity.	  For	  TRAIL-­‐based	  combinational	  therapy	  the	  agents/strategies	  that	  have	  been	  tested	  are	  listed	  on	  	  (Table	  
3)	   [Ravi,	   2004;	   Frese,	   2002;	   Jin,	   2004;	   Hylander,	   2005;	   Vignati,	   2002;	   Cuello,	   2001;	  
Mizutani,	   1999;	   Brooks,	   2005;	   Johnson,	   2003;	   Zhu,	   2005;	   Ricci,	   2007;	   Kim,	   2008;	   Meng,	  
2007;	  Rosato,	  2007;	  Zangemeister-­‐Wittke,	  2003;	  Ray,	  2005;	  Li,	  2004a;	  Arnt,	  2002;	  Adams,	  
2007;	  Chai,	  2000;	  Fulda,	  2002;	  Li,	   2004b;	  Guo,	  2004;	  Maier,	  2011;	  Croce,	  2008;	  Garofalo,	  
2009]	  	  	  
Table	  3.	  Summary	  of	  anti-­‐cancer	  agents	  studied	  in	  combination	  with	  rh-­‐TRAIL	  	  
Mechanism	  of	  
action	  





Camptothecin,	  5-­‐fluorouracil,	  irinotecan,	  cisplatin,	  paclitaxel,	  doxorubicin,	  carboplatin,	  gemcitabine,	  adriamicin	   In	  vitro	  Paclitaxel,	  carboplatin,	  bevacizumab,	  cisplatin	  gemcitabine	   In	  vivo	  
Proteasome	  
inhibition	  
Bortezomib	   In	  vitro	  
Kinase	  inhibition	   Sorafenib	   In	  vitro	  
Bcl-­‐2	  inhibition	   Genasense	   In	  vitro	  BH3I-­‐2’	   In	  vitro	  
IAP	  inhibition	   Smac	  peptides	   In	  vitro	  and	  in	  vivo	  
HDACs	  inhibition	   TSA,	  SAHA,	  LAQ824	   In	  vitro	  
miRNAs	  
modulation	  
Strategies	  increasing	  miR-­‐212	  and	  strategies	  decreasing	  miR-­‐221	  and	  miR-­‐222	   In	  vitro	  Abbreviations:	   TRAIL,	   TNF-­‐releated	   apoptosis-­‐inducing	   ligand;	   BH3I,	   BH3	   inhibitor;	   IAP,	   inhibitor	   of	   apoptosis	   proteins;	  HDACs,	  histone	  deacetylases;	  miRNA	  and	  miR,	  microRNA.	  (Adapted	  from	  Bernardi,	  2012a)	   	  
 15 
Potential	  role	  of	  TRAIL	  in	  the	  management	  of	  autoimmune	  diabetes	  	  
2.1	  Type	  1	  diabetes	  mellitus	  	  Type	  1	  diabetes	  mellitus	  (T1DM)	   is	  an	  autoimmune	  disease	  whose	   incidence	  has	  been	  steadily	   increasing	  worldwide	   since	   the	  middle	  of	   the	  20th	   Century.	  Recently,	   the	   increase	   in	  T1DM	   incidence	  has	  been	  even	   faster	   than	  before	  and	   it	   is	   expected	   that	   the	  number	  of	  new	  cases	  diagnosed	  at	  or	  before	  14	  years	  of	   age	  will	  double	   in	   the	  next	  15	  years	  and	   the	  age	  of	  onset	  will	   be	   younger	   (0-­‐4	   years)	   [Harjutsalo,	   2008].	   It	   has	   been	   shown	   that	   T1DM	   results	  from	   an	   autoimmune	   β-­‐cell	   destruction	   and	   when	   70-­‐80%	   of	   the	   β-­‐cell	   mass	   has	   been	  destroyed	   the	   residual	   functional	   β-­‐cells	   are	   insufficient	   in	   number	   to	   maintain	   glucose	  tolerance	  [Van	  Belle,	  2011].	  At	  this	  stage,	  the	  lack	  of	  insulin	  leads	  to	  hyperglycemia	  and	  T1DM	  becomes	  clinically	  apparent	  [Van	  Belle,	  2011].	  	  	  T1DM	   therapy	   is	   based	   on	   the	   use	   of	   insulin.	   Despite	   the	   improvements	   in	   insulin	  replacement	   regimens	   and	   devices,	   insulin	   remains	   a	   treatment	   that	   heavily	   affects	   patients’	  quality	  of	   life	  and	  retains	  some	   important	  side	  effects,	   such	  as	  hypoglycemic	  events,	   seizures	  and	   coma.	   Moreover,	   T1DM	   is	   still	   associated	   with	   substantial	   morbidity	   and	   mortality.	  Consequently,	  during	  the	  past	  20	  years,	  a	   lot	  of	   interest	  has	  been	  focused	  on	  developing	  new	  strategies	  that	  aim	  to	  prevent,	  delay,	  and	  treat	  T1DM.	  These	  strategies	  are	  based	  on	  targeting	  the	  immune	  system	  [Bernardi,	  2012b].	  In	  contrast	  to	  the	  broadly	  immunosuppressive	  agents	  that	  were	  used	  initially,	  failed	  to	  produce	  lasting	  remission,	  and	  were	  associated	  with	  multiple	  long-­‐term	   side	   effects,	   new	   rationally	   designed	   agents	   have	   shown	   to	   possess	   the	  characteristics	  to	  successfully	  prevent	  or	  delay	  T1DM	  development	  [Van	  Belle,	  2011;	  Feutren,	  
1986;	  Dupré,	  1988;	  Raz,	  2001;	  Herold,	  2005;	  Lugdvisson,	  2012;	  Hu,	  2007].	  TRAIL	  is	  one	  of	  these	  agents,	  given	  that	  by	  regulating	  the	  homeostasis	  of	  the	  immune	  system	  it	  seems	  to	  delay	  T1DM	  natural	  history	  without	  causing	  adverse	  effects	  [Di	  Pietro,	  2004;	  Secchiero,	  2008].	  	  	  
2.2	  Autoimmunity	  in	  T1DM	  	   T1DM	  is	  an	  autoimmune	  disease	   in	  which	  CD4+	  and	  CD8+	  T	   lymphocytes	   infiltrate	   the	  Islets	   of	   Langerhans	   resulting	   in	   a	   cell-­‐mediated	   islets	   destruction,	   insulin	   deficiency	   and	  hyperglycemia.	   The	   concept	   that	   T1DM	   pathogenesis	   is	   immune-­‐mediated	   dates	   back	   to	   the	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sixties,	   when	   Burnet	   and	  Mackay	   included	   T1DM	   among	   several	   autoimmune	   diseases.	   Two	  years	  later,	  Gepts	  and	  colleagues	  found	  that	  the	  key	  pancreatic	  morphological	  feature	  in	  recent-­‐onset	  T1DM	  was	   an	   insulitis,	   suggesting	   that	   it	   is	   the	   immune	   system	   that	   is	   involved	   in	   the	  pathogenesis	  of	  the	  disease	  [Gepts,	  1965].	  Then,	  in	  1974	  the	  group	  of	  Nerup	  demonstrated	  that	  T1DM	   is	   a	   cell-­‐mediated	   autoimmune	   disease	   by	   incubating	   porcine	   islets	   with	   peripheral	  blood	  mononuclear	  cells	  of	  diabetic	  patients	  and	  reporting	  cell	  migration	  inhibition	  in	  diabetics	  as	  compared	  to	  normal	  controls	  	  [Nerup,	  1974].	  	  	  The	  current	  view	  on	  the	  human	  immunology	  of	  T1DM	  could	  be	  summarized	  as	  follows:	  T1DM	  is	  a	  T	  cell-­‐mediated	  disease.	  T	  cells	  are	  present	  in	  the	  islets,	  peri-­‐pancreatic	  lymphnodes	  and	  systemic	  circulation	  of	  T1DM	  patients.	  These	  cells	  are	  mostly	  CD8+	  lymphocytes,	  with	  only	  few	   macrophages	   and	   no	   T	   regulatory	   (Treg)	   cells,	   as	   to	   say	   that	   the	   distribution	   of	   T	   cell	  subsets	   is	   also	   abnormal	   [Buschard,	   1980]	   and	   that	   circulating	   Treg	   cells	   display	   defective	  responsiveness	   [Roncarolo,	   2007].	   The	   importance	   of	   Treg	   cells	   in	   the	  maintenance	   of	   self-­‐tolerance	  and	  immune	  homeostasis	  has	  been	  clearly	  shown	  by	  the	  development	  of	  T1DM	  and	  other	   polyendocrinopathies	   in	   patients	   with	   immune-­‐dysregulation	   polyendocrinopathy	  enteropathy	  X-­‐linked	  syndrome,	   caused	  by	   impairment	  of	  Treg	  cell-­‐mediated	  peripheral	   self-­‐tolerance	   [Sakaguchi,	   2012].	   On	   the	   other	   hand,	   the	   report	   that	   a	   patient	   with	   X-­‐linked	  agammaglobulinemia	  developed	  T1DM	  diabetes	  shows	   that	  neither	  autoantibodies	  nor	  B	  cell	  function	   seem	   to	   be	   critically	   involved	   in	   the	   pathogenesis	   of	   this	   disease	   [Martin,	   2001].	  Although	   the	   delivery	   of	   rituximab,	   which	   is	   an	   anti-­‐B	   cell	   antibody,	   protected	   NOD	   mice	  against	   T1DM	   development	   during	   the	   early	   stages	   of	   the	   disease	   [Hu,	   2007],	   the	   same	  treatment	  did	  not	  change	  the	  disease	  course	   in	  early	  onset	  T1DM	  patients	   [Pescovitz,	  2009],	  suggesting	   once	   again	   that	   cell-­‐mediated	   autoimmunity	   in	   T1DM	   corresponds	   to	   a	   T	   cell-­‐mediated	  response.	  	  As	   for	   the	   natural	   history	   of	   the	   disease,	   islet	   inflammation	   or	   insulitis	   generally	  precedes	   the	   onset	   of	   T1DM	   [Roep,	   1986]	   and	   autoantibodies	   are	   usually	   detectable	   at	   this	  stage	   [Eisenbarth,	   1986].	   These	   autoantibodies	   are	   directed	   against	   several	  molecules	   of	   β-­‐cells,	   such	   as	   insulin,	   insulinoma-­‐associated	   antigen	   (IA)-­‐2,	   65-­‐kD	   isoform	   of	   glutamic	   acid	  decarboxylase	   (GAD-­‐65),	   β-­‐cell-­‐specific	   zinc	   transporter	   (Znt8),	   and	   islet	   cell	   autoantibodies	  (ICA)-­‐512.	  The	  role	  and/or	  significance	  of	  these	  autoantibodies	  is	  not	  entirely	  clear,	  given	  that	  fetal	  exposure	  to	  GAD-­‐65	  and/or	  IA-­‐2	  autoantibodies	  may	  protect	  against	  diabetes	  [Bottazzo,	  
1978].	  Proinsulin,	  GAD-­‐65,	  IA-­‐2	  and	  Znt8	  are	  not	  only	  the	  major	  autoantibody	  targets	  but	  also	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the	  main	   epitopes	   activating	   autoreactive	   T	   cells	   [Koezwara,	   2004].	   Once	   T	   cells	   have	   been	  activated	  by	  the	  recognition	  of	  islet	  autoantigens	  via	  MHC	  class	  I	  [Di	  Lorenzo,	  2007]	  and	  II,	  β-­‐cells	   are	   destroyed	   either	   by	   CD8+	   lymphocytes	   through	   the	   release	   of	   cytolitic	   granules	  containing	  perforin	   and	  granzyme,	   or	  by	  both	  CD8+	  and	  CD4+	   lymphocytes	   through	  Fas	   and	  Fas-­‐ligand-­‐dependent	   interactions	   or	   the	   release	   of	   IL-­‐1β,	   TNF-­‐α,	   γ-­‐interferon	   (IFN-­‐γ)	  [Hamilton-­‐Williams,	  2003].	  	  	  	  
2.3	  Immunosuppressive	  strategies	  in	  T1DM	  or	  from	  cause	  to	  cure	  	   Given	  that	  autoimmunity	  appears	  to	  be	  the	  main	  effector	  mechanism	  in	  T1DM,	  several	  immunosuppressive	   agents	   have	   been	   studied	   as	   potential	   therapies	   for	   patients	   with	   new-­‐onset	   T1DM.	   The	   first	   agents	   studied	   were	   broadly	   immunosuppressive	   drugs	   including	  cyclosporine,	   nicotinamide,	   anti-­‐oxidant	   agents,	   heat	   shock	   proteins	   and	   anti-­‐CD3	   [Feutren,	  
1986;	  Dupré,	  1988;	  Raz,	  2001;	  Herold,	  2005].	  Unfortunately,	  most	  attempts	  either	  achieved	  minimal	  benefits	  or	  the	  adverse	  effects	  outweighed	  their	  benefits.	  One	  of	  the	  main	  side	  effects	  of	  cyclosporine	  was,	  for	  example,	  the	  induction	  of	  nephropathy	  [Feutren,	  1986;	  Dupré,	  1988].	  So,	   the	   scientific	   interest	   moved	   to	   antigen-­‐specific	   interventions,	   which	   are	   more	   targeted	  forms	   of	   immunosuppression,	   aiming	   at	   inducing	   selective	   immunological	   tolerance	   by	   the	  systemic	   delivery	   of	   the	   autoantigens	   involved	   in	   T1DM.	   The	   delivery	   of	   these	   autoantigens,	  such	   as	  GAD-­‐65	   and	   insulin,	   should	   in	   fact	   induce	  Treg	   cell	   responses	   (active	   tolerance)	   and	  anergize	  autoreactive	  T	  cells	  (passive	  tolerance).	  Consistent	  with	  this	  rationale,	  in	  one	  of	  these	  studies	  GAD-­‐65	  treatment	  displayed	  a	  short	  protective	  effect	  on	  C-­‐peptide	  secretion	  in	  T1DM	  patients,	   who	   had	   been	   treated	   less	   than	   6	   months	   after	   diagnosis	   [Ludvigsson,	   2008].	  Nevertheless,	  the	  results	  coming	  from	  a	  more	  recent	  trial	  did	  not	  confirm	  the	  efficacy	  of	  such	  a	  treatment	  in	  the	  long-­‐term,	  as	  GAD-­‐65	  delivery	  failed	  to	  ameliorate	  T1DM	  natural	  history	  over	  15	  months	  [Ludvigsson,	  2012].	  	  	  Beside	  these	  immunosuppressive	  strategies,	  another	  therapeutic	  strategy	  against	  T1DM,	  which	   aims	   at	   curing	   this	   disease	   rather	   than	   just	   treating	   it,	   is	   islet	   transplantation.	   Islet	  transplantation	   has	   been	   shown	   to	   successfully	   restore	   endogenous	   insulin	   production	   and	  glycemic	  stability	  in	  subjects	  with	  T1DM	  and	  instable	  control	  [Ricordi,	  2003].	  In	  particular,	  the	  islet	  transplantation	  performed	  according	  to	  the	  Edmonton	  protocol	  has	  achieved	  reproducible	  insulin	   independence,	  with	  more	   than	   80%	  of	   recipients	   still	   insulin-­‐free	   at	   1	   year	   after	   the	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procedure	  [Shapiro,	  2006].	  Currently	  available	  data	  suggest	  that	  medium-­‐	  to	  long-­‐term	  results	  are	   still	   not	   achievable	   mainly	   because	   of	   the	   high	   frequency	   of	   non-­‐functioning	   grafts	   and	  secondary	  graft	  failure.	  Unfortunately,	  the	  methods	  that	  have	  been	  devised	  so	  far	  to	  protect	  β-­‐cells	  from	  immune	  destruction	  have	  only	  been	  able	  to	  delay,	  without	  preventing,	  the	  failure	  of	  the	  transplants	  and	  the	  consequent	  need	  of	  resuming	  the	  administration	  of	   insulin.	  Moreover	  all	   the	   adverse	   effects	   of	   long-­‐term	   general	   immunosuppression	   and	   late	   graft	   loss	   overall	  represent	  an	  obstacle	  for	  any	  successful	  transplantation	  [Battaglia,	  2006].	  	  	  
2.4	  TRAIL,	  autoimmune	  diseases,	  and	  T1DM	  	  A	  large	  amount	  of	  data	  has	  pointed	  out	  the	  ability	  of	  TRAIL	  to	  act	  as	  an	  immune	  system	  modulator	  [Di	  Pietro,	  2004;	  Secchiero,	  2008].	  TRAIL	  best-­‐known	  function	  is	  the	  induction	  of	  apoptosis,	  which	  occurs	  through	  the	  activation	  of	  the	  extrinsic	  apoptotic	  pathway,	  triggered	  by	  the	  binding	  of	  TRAIL	  to	  DRs,	  as	  discussed	  before.	  Beside	  its	  pro-­‐apoptotic	  effect,	  TRAIL	  is	  also	  able	  to	  activate	  pathways	  involved	  in	  cell	  survival.	  It	  has	  in	  fact	  been	  demonstrated	  that	  TRAIL	  is	   able	   to	   stimulate	   the	   survival	   and	  proliferation	  of	  both	  neoplastic	   and	  non-­‐neoplastic	   cells	  [Lancaster,	  2003;	  Ehrhardt,	  2003;	  Secchiero,	  2004;	  Morel,	  2005].	  The	  TRAIL-­‐mediated	  pro-­‐survival	  effect	  seems	  to	  be	  due	   to	   the	  recruitment	  of	  adaptor	  molecules	   that	   interact	  directly	  with	  DRs	  death	  domains.	  This	  would	  block	  the	  progression	  of	  the	  pro-­‐apoptotic	  signal.	   In	  the	  meantime,	   TRAIL	   would	   be	   able	   to	   engage	   other	   intracellular	   pathways	   and	   mediators,	  including	   NF-­‐κB,	   JNK,	   MAPK/ERK	   and	   Akt,	   leading	   to	   subsequent	   transcription	   of	   survival	  genes	   [Morel,	   2005;	   Secchiero,	   2004].	   TRAIL	   ability	   of	   activating	   diametrically	   opposed	  pathways	  may	  actually	  be	  ascribed	  to	  cell	  responsiveness,	  rather	  than	  to	  the	  ligand	  properties.	  Cell	  responsiveness	  to	  TRAIL	  could	  result	  from	  the	  balance	  between	  death	  and	  decoy	  receptors	  expressed	   on	   the	   cell	   surface	   [Lincz,	   2001;	  Wutcher,	   2001;	   Mirandola,	   2004;	   Kim,	   2000],	  which	   in	  turn	  could	  come	  down	  to	  the	  cellular	   incorporation	  of	  specific	   intracellular	  proteins	  into	  “lipid	  rafts”	  [Hunter,	  2006;	  Song,	  2007].	  Lipid	  rafts	  are	  platforms	  consisting	  of	  a	  dynamic	  pool	  of	  cholesterol	  and	  sphingolipids,	  which	  recruit	  signalling	  molecules	  including	  cell	  surface	  receptors.	  Independent	  studies	  have	  documented	  a	  redistribution	  of	  TRAIL	  receptors	  and	  DISC	  components	  from	  “non-­‐rafts”	  into	  lipid	  rafts	  suggesting	  that	  this	  event	  could	  switch	  apoptosis	  instead	  of	  survival	  [Song,	  2007].	  However,	  a	  correlation	  between	  TRAIL	  receptors	  balance	  (i.e.,	  death/decoy	  receptor	  ratio)	  and	  protection	  versus	  susceptibility	   to	  apoptosis	  has	  never	  been	  clearly	  demonstrated	  and	  it	  is	  still	  under	  debate.	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  Going	  back	  to	  T1DM,	  TRAIL	  is	  expressed	  on	  the	  surface	  of	  activated	  immune	  cells,	  such	  as	   NK	   cells,	   T	   cells,	  macrophages	   and	   dendritic	   cells,	   where	   it	   apparently	  mediates	   immune	  surveillance,	   particularly	   against	   hematological	   malignancies	   and	   autoimmune	   diseases	  [Secchiero,	  2008].	  Studies	  on	  TRAIL	  -­‐/-­‐	  mice	  demonstrate	  that	  mice	  without	  TRAIL	  are	  viable	  and	   fertile,	   but	   more	   susceptible	   to	   autoimmune	   arthritis,	   experimental	   autoimmune	  encephalomyelitis	   and	   autoimmune	   diabetes,	   indicating	   a	   clear	   role	   for	   TRAIL	   in	   immune	  regulation.	  In	  addition,	  TRAIL	  involvement	  in	  immune	  surveillance	  has	  also	  been	  proved	  by	  the	  acceleration	  of	  experimental	  autoimmune	  encephalomyelitis	   (EAE)	  and	  autoimmune	  arthritis	  that	   followed	  TRAIL	  blockade	   [Cretney,	  2002;	   Sedger,	  2002].	   Interestingly,	   in	   the	  models	   of	  EAE	  TRAIL-­‐deficient	  mice	  display	  significantly	   lower	  Treg	  cells	  than	  wild-­‐type	  mice,	  as	  to	  say	  that	  TRAIL	  not	  only	  inhibits	  autoreactive	  T	  cells	  but	  also	  promotes	  Treg	  cells	  [Ikeda,	  2010].	  	  Lamhamedi-­‐Cherradi	   and	   colleagues	   are	   the	   first	   who	   have	   demonstrated	   that	   either	  blockade	   or	   TRAIL	   deficiency	   exacerbates	   T1DM	   [Lamhamedi-­‐Cherradi,	   2003].	   The	   first	  animal	  model	  consisted	  of	  NOD	  mice	  injected	  with	  a	  soluble	  TRAIL	  receptor	  (sDR5/TRAIL-­‐R2)	  in	  order	  to	  block	  TRAIL	  functions.	  In	  the	  mice	  injected	  with	  sDR5/TRAIL-­‐R2,	  T1DM	  incidence	  increased	   significantly	   and	   its	   onset	   was	   also	   significantly	   accelerated	   with	   respect	   to	   the	  control	  group.	  In	  addition,	  the	  blockade	  of	  TRAIL	  by	  sDR5/TRAIL-­‐R2	  led	  to	  greater	  pancreatic	  inflammation	  as	  well	  as	  to	  enhanced	  cellular	  and	  humoral	  immune	  responses,	  with	  an	  increase	  in	  T	  cells	  proliferation	  and	  pro-­‐inflammatory	  response	  as	  well	  as	  higher	  levels	  of	  anti-­‐GAD-­‐65	  [Lamhamedi-­‐Cherradi,	  2003].	  The	  second	  animal	  model	  consisted	  of	  TRAIL	  -­‐/-­‐	  mice	  injected	  with	   streptozotocin,	   which	   is	   a	   drug	   that	   destroys	   β-­‐cells	   and	   therefore	   cause	   diabetes.	   The	  findings	   observed	   in	   the	   diabetic	   TRAIL	   -­‐/-­‐	   mice	   recapitulated	   those	   observed	   in	   the	   sDR5	  treated	   NOD	   mice,	   since	   the	   incidence	   of	   T1DM	   increased	   significantly	   and	   its	   onset	   was	  significantly	   accelerated.	   Consistent	   with	   these	   observations,	   the	   administration	   of	  recombinant	   soluble	   TRAIL	   in	   streptozotocin-­‐injected	   mice	   preserved	   pancreatic	   islets	   and	  significantly	  ameliorated	  the	  severity	  of	  T1DM,	  by	  lowering	  glucose	  levels	  [Zauli,	  2010].	  	  	  
2.5	  Possible	  mechanisms	  whereby	  TRAIL	  protects	  against	  T1DM	  	  Having	   said	   that,	   the	   molecular	   mechanisms	   whereby	   TRAIL	   blockade	   exacerbates	  T1DM	  and,	   on	   the	   contrary,	   its	   delivery	   ameliorates	   the	   natural	   history	   of	   this	   disease,	   have	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only	   partly	   been	   clarified.	   One	   of	   the	   studies	   addressing	   this	   issue	   showed	   that	   TRAIL	  suppressed	  the	  proliferation	  of	  autoreactive	  T	  cells	  isolated	  from	  diabetic	  NOD	  mice	  [Mi,	  2003].	  This	   effect	   was	   explained	   by	   the	   finding	   that	   TRAIL	   up-­‐regulated	   p27	   expression	   and	  simultaneously	   inhibited	  IL-­‐2	  production	  by	  autoreactive	  T	  cells.	  With	  respect	  to	  this	   issue,	   it	  has	  indeed	  been	  shown	  that	  the	  up-­‐regulation	  of	  cdk	  inhibitors,	  such	  as	  p27,	  which	  sequester	  cyclin	  D2-­‐cdk4	  and	  cyclin	  E–cdk2	  complexes,	  stops	  the	  progression	  of	  the	  cell	  cycle,	  preventing	  the	   progression	   of	   T	   cells	   through	   the	   G1	   restriction	   point	   of	   the	   cell	   cycle,	   and	   therefore	  anergizing	  autorective	  T	   cells	   [Mi,	  2003].	  On	   the	  other	  hand,	   it	   has	  been	   shown	   that	   the	   cell	  exposure	   to	   IL-­‐2	   promotes	   the	   degradation	   of	   p27	   and	   the	   entry	   into	   S	   phase	   [Appelman,	  
2001];	   therefore	   IL-­‐2	   inhibition	  by	  TRAIL	  could	  be	  an	  additional	  mechanism	  whereby	  TRAIL	  anergizes	  diabetogenic	  T	  cells.	  	  	  Recent	   works	   suggest	   that	   beside	   T	   cells	   anergy	   TRAIL	   could	   also	   promote	   β	   cell	  survival.	   In	  vitro	   experiments	  performed	  on	  rat	   insulinoma	  cells	   (INS-­‐1),	  which	  are	  used	  as	  a	  model	  for	  the	  study	  of	  pancreatic	  β-­‐cells,	  have	  shown	  that	  exposure	  to	  soluble	  TRAIL	  does	  not	  affect	  β-­‐cell	  viability,	  but,	  by	  promoting	  the	  activation	  of	  NF-­‐kB,	  it	  upregulates	  the	  expression	  of	  its	  decoy	  receptor	  TRAIL-­‐R3	  (DcR1),	  which	  in	  turns	  should	  prevent	  apoptosis	  [Kang,	  2010a].	  In	  this	  context,	  the	  selective	  increase	  of	  TRAIL	  and	  DcR1	  expression	  in	  the	  pancreatic	  islets	  in	  NOD	   mice,	   which	   occurs	   in	   streptozotocin-­‐induced	   T1DM,	   has	   been	   proposed	   as	   part	   of	   a	  defensive	  strategy	  of	  the	  β-­‐cell	  against	  infiltrating	  leukocytes	  [Dirice,	  2011].	  	  	  Kang	  and	  colleagues	  have	  further	  investigated	  TRAIL	  protective	  effects	  in	  T1DM	  animal	  models,	  demonstrating	  that	  they	  could	  be	  partly	  attributed	  to	  the	  elevation	  of	  tissue	  inhibitor	  of	  metalloproteinase-­‐1	   (TIMP-­‐1)	   levels	   that	   follows	   TRAIL	   delivery	   [Kang,	   2010b].	   In	   vivo	  experiments	   have	   in	   fact	   demonstrated	   that	   TRAIL-­‐induced	   TIMP-­‐1	   elevation	   markedly	  reduced	  MMP-­‐9	   pancreatic	   activity,	   thus	   protecting	   against	   T1DM	   development/progression	  [Kang,	   2010b],	   given	   that	   circulating	  MMP-­‐9	   is	   higher	   in	   diabetic	   patients	   and	   that	   MMP-­‐9	  cleaves	   insulin	   [Maxwell,	   2001;	   Descamps,	   2004;	   Xue,	   2005].	   The	   in	   vivo	   data	   are	   further	  supported	  by	  in	  vitro	  data	  showing	  that	  the	  addition	  of	  TIMP-­‐1	  significantly	  reduces	  INS-­‐1	  cells	  death	   [Kang,	   2010b],	   consistent	   with	   a	   previous	   report	   showing	   that	   TIMP-­‐1	   prevents	  cytokine-­‐mediated	  dysfunction	  and	  cytotoxicity	  in	  pancreatic	  islets	  and	  β-­‐cell	  [Han,	  2001].	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2.6	  TRAIL	  and	  diabetic	  complications	  	  It	   is	   well	   known	   that	   T1DM	   morbidity	   and	   mortality	   are	   primarily	   due	   to	   diabetic	  complications.	  Diabetic	   complications	   are	   divided	   into	  macrovascular	   and	  microvascular	   and	  they	   include	   acute	   myocardial	   infarction,	   stroke,	   peripheral	   artery	   disease,	   diabetic	  nephropathy,	   retinopathy	   and	   neuropathy	   [Calcutt,	   2009].	   Experimental	  works	   suggest	   that	  TRAIL	  may	  protect	  against	  diabetic	  complications.	  With	  respect	  to	  cardiovascular	  diseases,	  our	  group	   has	   demonstrated	   that	   TRAIL	   delivery	   significantly	   reduced	   the	   development	   of	  atherosclerotic	   lesions	   and	   contributed	   to	   plaque	   stabilization	   by	   decreasing	   the	   number	   of	  infiltrating	   macrophages	   and	   increasing	   the	   number	   of	   vascular	   smooth	   muscle	   cells	   in	   an	  animal	   model	   of	   T1DM	   [Secchiero,	   2006].	   The	   concept	   that	   TRAIL	   might	   protect	   against	  cardiovascular	   diseases,	   is	   supported	   by	   the	   finding	   that	   circulating	   TRAIL	   is	   significantly	  reduced	  in	  different	  cohorts	  of	  patients	  with	  acute	  coronary	  syndrome	  and	  heart	   failure	  with	  respect	   to	   patients	   with	   stable	   angina	   or	   healthy	   coronary	   arteries	   [Michowitz,	   2005;	  
Schoppet,	  2006;	  Secchiero,	  2009].	   In	  addition	  to	  the	  anti-­‐atherosclerotic	  properties	  of	  TRAIL	  we	  have	  also	  demonstrated	   that	  TRAIL	  delivery	  protects	   against	  myocardial	   fibrosis	   and	   cell	  apoptosis	  in	  an	  animal	  model	  of	  diabetic	  cardiomyopathy	  [Toffoli,	  2012],	  which	  corresponds	  to	  the	   stage	   in	   which	   ventricular	   dysfunction	   develops	   in	   diabetic	   patients	   in	   the	   absence	   of	  coronary	  atherosclerosis	  and	  hypertension.	  	  	  	  In	  contrast	  to	  what	  has	  been	  found	  in	  experimental	  models	  of	  cardiovascular	  diseases,	  TRAIL	  unfortunately	  does	  not	  seem	  to	  protect	  againt	  diabetic	  microvascular	  complications.	  In	  an	  animal	  model	  of	  diabetic	  nephropathy	  Lorz	  and	  colleagues	  [Lorz,	  2008]	   found	  that	  TRAIL	  gene	  and	  protein	  expression	  was	  significantly	  increased	  in	  both	  glomeruli	  and	  tubuli	  of	  diabetic	  kidneys.	  In	  following	  in	  vitro	  experiments	  it	  was	  found	  that	  TRAIL	  actually	  induced	  tubular	  cell	  apoptosis,	   which	  was	   enhanced	   by	   the	   concomitant	   presence	   of	   pro-­‐inflammatory	   cytokines	  and	   high	   glucose	   levels.	   This	  would	   suggest	   that	   TRAIL	   could	   play	   an	   important	   role	   in	   the	  progression	   of	   diabetic	   nephropathy.	   The	   concept	   that	   TRAIL	  may	   play	   a	   role	   in	   the	   natural	  history	   of	   diabetic	   complications	   is	   further	   supported	   by	   the	   observation	   that	   patients	   with	  proliferative	  diabetic	  retinopathy	  exhibited	  lower	  levels	  of	  TRAIL	  in	  the	  conjunctival	  sac	  fluid	  with	   respect	   to	   patients	   with	   non-­‐proliferative	   diabetic	   retinopathy	   or	   without	   diabetic	  retinopathy	  [Secchiero,	  2011].	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High-­‐fat	  diet	  and	  type	  2	  diabetes	  mellitus	  	  
3.1	  Obesity	  and	  type	  2	  diabetes	  mellitus	  	   Type	   2	   diabetes	   mellitus	   (T2DM)	   represents	   a	   heterogeneous	   group	   of	   disorders	  characterized	   by	   insulin	   resistance	   and	   impaired	   insulin	   secretionand	   defined	   by	   a	   raised	  fasting	   or	   post-­‐challenge	   blood	   glucose.	   T2DM	   incidence	   is	   increasing	   to	   the	   point	   that	   it	   is	  reaching	   epidemic	   proportions.	   Recent	   studies	   show	   that	   T2DM	   prevalence	   is	   strongly	  associated	  with	  overall	  obesity	  and	  central	  obesity,	  mainly	  due	  to	  unhealthy	  changes	  in	  lifestyle	  [Yang,	   2010].	   It	   has	   in	   fact	   been	   shown	   that	   obesity	   is	   an	   independent	   predictor	   of	   insulin	  resistance	   and	   T2DM	   [Collins,	   2011]	   and	   that	   weight	   loss	   prevents	   it	   [Tuomilheto,	   2011].	  Among	  the	  multiple	  mechanisms	  linking	  obesity	  to	  diabetes,	  inflammation	  is	  a	  common	  feature	  that	  has	  been	  implicated	  in	  the	  pathophysiology	  of	  both	  diseases.	  	  	  	  
3.2	  Lipotoxicity	  and	  T2DM	  	   It	   has	   been	   argued	   that	   another	   mechanism	   explaining	   insulin	   resistance	   and	  compromised	  β-­‐cell	  function	  in	  T2DM	  is	  a	  breakdown	  in	  lipids	  dynamics.	  This	  is	  often	  reflected	  by	  elevated	  levels	  of	  circulating	  free	  fatty	  acids	  (FFA)	  and	  tryglicerides,	  together	  with	  excessive	  deposition	   of	   fat	   in	   various	   extra-­‐adipose	   tissues	   including	   the	   muscle	   bed	   and	   the	   β-­‐cells.	  Increased	   tissue	   levels	   of	   FFA	   have	   been	   shown	   to	   cause	   the	   β-­‐cell	   abnormalities	   of	   non-­‐diabetic	  obesity	  and	  ultimately	  result	  in	  obesity-­‐dependent	  diabetes	  [Unger,	  2011].	  A	  western	  diet	  that	  is	  high	  in	  fat	  will	  therefore	  result	  in	  loss	  of	  β-­‐cells,	  by	  pancreatic	  FFA	  deposition	  that	  in	  turn	   promotes	   lipoapoptosis	   as	  well	   as	   peripheral	   glucose	   intolerance	   due	   to	   lipid	   excess	   in	  skeletal	  muscle.	  	  	  
3.3	  Animal	  models	  of	  T2DM	  	   T2DM	   animal	   models	   are	   likely	   to	   be	   as	   complex	   and	   heterogeneous	   as	   the	   human	  condition.	   [Chatzigeorgiou,	   2009]	  However,	   since	   obesity	   is	   the	  major	   environmental	   factor	  predisposing	  to	  T2DM	  (although	  2/3	  of	  obese	  subjects	  do	  not	  become	  diabetics),	  the	  ability	  of	  an	  animal	  model	  to	  develop	  firstly	  obesity	  and	  then	  T2DM	  is	  one	  of	  the	  most	  important	  criteria	  for	  selecting	  a	  model.	  T2DM	  murine	  models	  are	  summarized	  on	  Table	  4.	  
 23 
	  
3.4	  High-­‐fat	  feeding	  as	  a	  model	  for	  the	  study	  of	  T2DM	  	  	  	  Rodent	   models,	   both	   genetic	   and	   dietary	   (Table	   4),	   are	   commonly	   used	   to	   examine	   the	  mechanosms	  underlying	  the	  development	  of	  insulin	  resistance	  in	  the	  setting	  of	  obesity.	  Many	  of	  these	  animal	  models,	  such	  as	  the	  high-­‐fat	  fed	  rodents	  and	  those	  with	  an	  absence/impairment	  of	  leptin	  signalling,	  are	  absed	  on	  the	  fact	  that	  an	  over	  supply	  of	  lipids	  has	  been	  identified	  as	  a	  key	  factor	  leading	  to	  obesity	  and	  insulin	  resistance	  [Turner,	  2007].	  Male	  mice	  C57Bl6	  8	  weeks	  old,	  high-­‐fat	  fed	  for	  12	  weeks	  become	  obese	  and	  develop	  a	  mild	  form	  of	  T2DM	  compared	  to	  control	  mice.	  	  In	  particular	  we	  have	  found	  [Bernardi,	  submitted	  data]:	  (i)	  fat	  deposition;	  (ii)	  hyperglycemia,	  hyperinsulinemia	  and	  insulin	  resistance	  (Figure	  2);	  (iii)	  low-­‐grade	  inflammation	  (Figure	  3).	  In	  conclusion,	   high-­‐fat	   fed	   C57Bl6	   mice	   develop	   a	   form	   of	   obesity-­‐induced	   T2DM	   presumably	  caused	  by	  an	  accumulation	  of	   lipidsleading	   to	  dysfunction	  of	  pancreatic	   islets	  and	  peripheral	  organs	  as	  well	  as	  adipose	  tissue	  enlargement	  and	  low-­‐grade	  inflammation.	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Table	  4.	  Rodent	  models	  of	  T2DM	  
Type	  of	  animal	  
model	  







ob/ob	  mouse	  db/db	  mouse	  Zucker	  (fa/fa)	  fatty	  rat	  KK	  (Kuo	  Kondo)	  mouse	  KK/Ay	  (yellow	  KK	  obese)	  mouse	  NZO	  (New	  Zeland	  obese)	  mouse	  NONcNZO10	  mouse	  OLETF	  (Otsuka	  Long	  Evans	  Tokushima	  fatty)	  rat	  ZDF	  (Zucker	  diabetic	  fatty)	  rat	  JCR/LA-­‐cp	  (James	  C	  Russell/LA	  corpulent)	  rat	  SHR/N-­‐cp	  (spontaneously	  hypertensive	  rat/NIH-­‐corpulent)	  rat	  M16	  mouse	  TSOD	  (Tsumara	  Suzuki	  obese	  diabetes)	  mouse	  
Non-­‐obese	  C57Bl6	  (Akita)	  mutant	  mouse	  ALS	  (alloxan	  sensitive)/Lt	  mouse	  
Diet/nutrition-­‐
induced	  models	  
Israeli	  Sand	  rat	  (Psammomys	  obesus)	  Spiny	  mouse	  
C57Bl6J	  mouse	  
	  	  	  
Chemically-­‐induced	   GTG	  (goldthioglucose)	  treated	  obese	  mouse	   ALX	  or	  STZ	  adult	  models	  	  Neonatal	  STZ	  rat	  
Surgically-­‐induced	   VMH	  (ventromedial	  hypothalamus)	  lesioned	  dietary	  obese	  rat	   Partial	  pancreatectomized	  animals	  
Genetically	  modified	  
animals	  
β3	  receptor	  	  -­‐/-­‐	  mouse	  UCP1	  (uncoupling	  protein)	  	  	  -­‐/-­‐	  mouse	  
Transgenic	  or	  -­‐/-­‐	  mice	  of	  genes	  implicated	  in	  insulin	  resistance	  (e.g.	  IRS-­‐1,	  IRS-­‐2,	  GLUT-­‐4),	  lipid	  and	  glucose	  metabolism	  (e.g.	  PPARs)	  and	  insulin	  secretion	  (GLUT-­‐2,	  Glukokinase,	  IGF-­‐IR),	  human	  islet	  amyloid	  polypeptide	  (hIAPP)	  transgenic	  rodents	  
	  
(Adapted	  from	  Chatzigeorgiou,	  2009)	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3.4	  High-­‐fat	  feeding	  as	  a	  model	  for	  the	  study	  of	  T2DM	  	  	  	  Rodent	   models,	   both	   genetic	   and	   dietary	   (Table	   4),	   are	   commonly	   used	   to	   examine	   the	  mechanosms	  underlying	  the	  development	  of	  insulin	  resistance	  in	  the	  setting	  of	  obesity.	  Many	  of	  these	  animal	  models,	  such	  as	  the	  high-­‐fat	  fed	  rodents	  and	  those	  with	  an	  absence/impairment	  of	  leptin	  signalling,	  are	  absed	  on	  the	  fact	  that	  an	  over	  supply	  of	  lipids	  has	  been	  identified	  as	  a	  key	  factor	  leading	  to	  obesity	  and	  insulin	  resistance	  (Turner,	  2007).	  Male	  mice	  C57Bl6	  8	  weeks	  old,	  high-­‐fat	  fed	  for	  12	  weeks	  become	  obese	  and	  develop	  a	  mild	  form	  of	  T2DM	  compared	  to	  control	  mice.	  	  In	  particular	  we	  have	  found	  (Bernardi,	  submitted	  data):	  (i)	  fat	  deposition;	  (ii)	  hyperglycemia,	  hyperinsulinemia	  and	  insulin	  resistance	  (Figure	  2);	  (iii)	  low-­‐grade	  inflammation	  (Figure	  3).	  In	  conclusion,	   high-­‐fat	   fed	   C57Bl6	   mice	   develop	   a	   form	   of	   obesity-­‐induced	   T2DM	   presumably	  caused	  by	  an	  accumulation	  of	   lipidsleading	   to	  dysfunction	  of	  pancreatic	   islets	  and	  peripheral	  organs	  as	  well	  as	  adipose	  tissue	  enlargement	  and	  low-­‐grade	  inflammation.	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Figure	  2.	  Glucose	  and	  insulin	  in	  high-­‐fat	  diet	  fed	  mice	  Blood	  glucose	  (mM)	  at	  0,	  15,	  16	  and	  120	  min	  during	  an	  IPGTT	  performed	  after	  6	  weeks	  (A)	  and	  12	  weeks	  (B)	  of	  HFD;	  Serum	  insulin	  (mM)	  at	  0,	  15,	  16	  and	  120	  min	  during	  an	  IPGTT	  performed	  after	  6	  weeks	  (C)	  and	  12	  weeks	  (D)	  of	  HFD;	  Blood	  glucose	  (mM)	  at	  0,	  15,	  16	  and	  120	  min	  during	  an	  IPITT	  performed	  after	  6	  weeks	  (E)	  and	  12	  weeks	  (F)	  of	  HFD.	  Data	  are	  reported	  as	  mean	   ±	   SEM;	   *	   p<0.05	   vs	   C57	   chow.	   Abbreviations:	   chow,	   chow	   fed;	   HF,	   high-­‐fat	   det	   fed;	   HFD,	   high-­‐fat	   diet;	   IPGTT,	  intraperitoneal	  glucose	  tolerance	  test;	  IPITT,	  intraperitoneal	  insulin	  tolerance	  test	  (Bernardi,	  submitted	  data).	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Figure	  3.	  High-­‐fat	  diet-­‐induced	  pro-­‐inflammatory	  changes	  Circulating	  levels	  of	  IL-­‐6;	  MCP-­‐1;	  and	  TNF-­‐	  α	  in	  C57	  chow	  (n=9)	  and	  C57	  HF	  (n=9)	  mice.	  Data	  is	  expressed	  as	  mean	  ±	  SEM.	  *	  p	  <	  0.05	   vs	   C57	   chow;	   †	   p	   <	   0.005	   vs	   C57	   chow.	   Chow,	   chow	   fed;	   HF,	   high-­‐fat	   diet	   fed;	   IL-­‐6,	   interleukin-­‐6;	   MCP-­‐1,	   monocyte	  chemotactic	  protein-­‐1;	  TNF-­‐α,	  tumor	  necrosis	  factor-­‐α.	  (Bernardi,	  submitted	  data)	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Introduction	  and	  aim	  of	  the	  study	  	  TRAIL	   is	   a	  member	   of	   the	   TNF	   superfamily	   of	   proteins,	   expressed	   either	   as	   a	   type	   II	  membrane	  or	  as	  a	  soluble	  protein	  [Di	  Pietro,	  2004].	  Among	  the	  putative	  physiological	  activities	  of	   TRAIL,	   the	   best-­‐characterized	   function	   is	   the	   induction	   of	   apoptosis	   in	   tumor,	   infected	   or	  transformed	   cells,	   while	   leaving	   most	   non-­‐transformed	   cells	   unharmed.	   TRAIL	   and	   its	  receptors	   have	   initially	   been	   implicated	   in	   immune	   surveillance,	   in	   particular	   against	  hematological	   malignancies	   [Secchiero,	   2008].	   Besides	   having	   been	   extensively	   studied	   as	  anticancer	  agent,	  TRAIL	  has	  also	  shown	  some	  therapeutic	  potential	  as	  anti-­‐atherosclerotic	  and	  anti-­‐diabetogenic	   molecule.	   In	   particular,	   in	   recent	   experimental	   works	   TRAIL	   was	   able	   to	  reduce	  the	  accelerated	  atherosclerosis	  observed	  in	  streptozotocin	  (STZ)-­‐treated	  ApoE-­‐/-­‐	  mice	  [Secchiero,	   2006]	   and	   to	   ameliorate	   the	   natural	   history	   of	   T1DM,	   due	   to	   its	   pro-­‐apoptotic	  properties	  against	  activated	  macrophages	  and	  T	  cells	  [Zauli,	  2010].	  	  The	  first	  experimental	  evidences	  demonstrating	  TRAIL	  effects	  on	  T1DM	  were	  presented	  by	   Lamhamedi-­‐Cherradi	   and	   colleagues	   [Sedger,	   2002;	   Mi,	   2003;	   Lamhamedi-­‐Cherradi,	  
2003],	  proving	  that	  blockade	  of	  TRAIL	  signalling	  in	  NOD	  mice,	  or	  diabetes	  induction	  by	  STZ	  in	  TRAIL-­‐/-­‐	  mice,	  significantly	  worsened	  the	  natural	  history	  of	  the	  disease.	  Consistent	  with	  these	  earlier	  observations,	  our	  group	  has	  shown	  that	  TRAIL	  treatment	  reduces	  significantly	  glucose	  levels	   in	  rats	  with	  STZ-­‐induced	  T1DM	  [Zauli,	  2010].	  This	  could	  be	  explained	  with	   the	  potent	  immune-­‐regulatory	  effect	  of	  TRAIL,	  which	  therefore	  could	  be	  protective	  towards	  T1DM.	  	  Whether	   TRAIL	   could	   ameliorate	   T2DM	   has	   only	   partially	   been	   answered.	   T2DM	   has	  been	   suggested	   to	   be	   caused	  by	   a	   breakdown	   in	   lipids	   dynamics,	   often	   reflected	  by	   elevated	  levels	   of	   triglycerides	   and	   circulating	   free	   FFA,	  which	  would	   ultimately	   lead	   to	   an	   excessive	  deposition	   of	   fat	   in	   various	   non-­‐adipose	   tissues	   causing	   insulin	   resistance	   and	   β-­‐cells	  abnormalities.	  High-­‐fat	  diet	  (HFD)	  is	  given	  to	  reproduce	  obesity-­‐induced	  insulin	  resistance,	  and	  T2DM	  [Turner,	  2007].	  Di	  Bartolo	  and	  colleagues	  have	  found	  that	  TRAIL-­‐/-­‐	  ApoE-­‐/-­‐	  mice	  on	  a	  HFD	   gained	   more	   body	   weight	   and	   that	   they	   displayed	   higher	   fasting	   glucose	   and	   pro-­‐inflammatory	  cytokines	  levels	  than	  ApoE-­‐/-­‐	  mice	  [Di	  Bartolo,	  2011].	  So,	  we	  hypothesized	  that	  TRAIL	   delivery	   could	   reduce	   body	   weight,	   lower	   fasting	   glucose	   and	   pro-­‐inflammatory	  cytokines	   levels,	   overall	   ameliorating	   T2DM.	   On	   this	   basis,	   the	   aim	   of	   our	   study	   was	   to	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determine	  whether	  systemic	  TRAIL	  delivery	  would	  prevent	  the	  metabolic	  abnormalities	  due	  to	  a	  HFD	  in	  C57Bl6	  mice	  [Bernardi,	  2012c].	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Materials	  and	  methods	  
	  
4.1	  Animals	  and	  Experimental	  protocol	  	   Twenty-­‐seven	  wild-­‐type	  male	  mice	   C57bl6	   aged	   8	  weeks	  were	   randomly	   allocated	   to	  standard	  chow	  diet	  (C57	  chow),	  HFD	  (C57	  HF)	  or	  HFD	  +	  TRAIL	  (C57	  HF	  +	  TRAIL)	  for	  12	  weeks.	  The	  animals	  were	  kept	   in	  a	   temperature-­‐controlled	  room	  (22±1°C)	  on	  a	  12-­‐	  hours	   light/dark	  cycle	  with	   free	   access	   to	   food	   and	  water	   and	   they	  were	   fed	   ad	   libitum	   for	   the	   length	   of	   the	  study.	   The	   standard	   chow	   diet	   had	   19.6%	   of	   protein,	   4.6%	   of	   total	   fat,	   4.5%	   of	   crude	   fibre	  providing	  a	  digestible	  energy	  of	  14.3	  MJ/Kg,	  the	  HFD	  had	  22.6%	  of	  protein,	  23.5%	  of	  total	  fat,	  5.4%	  of	  crude	  fibre	  providing	  a	  digestible	  energy	  of	  19	  MJ/Kg.	  Whereas	  C57	  chow	  and	  C57	  HF	  mice	  were	  injected	  intraperitoneally	  (ip)	  100	  μl	  of	  saline,	  C57	  HF	  +	  TRAIL	  mice	  were	  injected	  ip	  10	  mg	  of	  TRAIL	  in	  100	  μl	  of	  saline	  every	  week	  for	  the	  12	  weeks	  of	  the	  study.	  The	  drug	  was	  a	  recombinant	   (r)	   human	   (h)	   histidine	   6-­‐tagged	   hTRAIL	   (114-­‐281),	   produced	   in	   bacteria	   and	  resuspended	   in	   buffered	   saline	   before	   the	   injection.	   Body	   composition	   and	   food	   intake	  were	  evaluated	  every	  four	  weeks	  in	  all	  the	  mice	  studied,	  then	  measurements	  by	  indirect	  calorimetry	  were	  performed	  at	  week	  eleven	  and	  IPGTT	  (intraperitoneal	  glucose	  tolerance	  test)	  and	  IPITT	  (intraperitoneal	  insulin	  tolerance	  test)	  were	  performed	  at	  week	  twelve.	  At	  the	  end	  of	  the	  study,	  the	  animals	  were	  then	  anesthetized	  by	  an	  ip	  injection	  of	  pentobarbitone	  at	  a	  dose	  of	  100	  mg/Kg	  body	  weight.	  Blood	  was	  collected	  from	  the	  left	  ventricle,	  centrifuged	  and	  plasma	  was	  stored	  at	  -­‐20°C	   for	   analysis.	   Adipose	   tissue,	   liver,	   and	   skeletal	   muscle	   were	   kept	   for	   further	   analysis.	  Principles	   of	   laboratory	   animal	   care	   were	   followed	   as	   well	   as	   specific	   national	   laws	   where	  applicable.	   This	   study	   was	   approved	   by	   the	   animal	   ethic	   committee	   AMREP	   (the	   number	   of	  
approval	  was	  0947	  and	  the	  study	  period	  was	  May	  2010	  -­‐	  May	  2012).	  	  
4.2	  Recombinant	  human	  TRAIL	  production	  	   	  	   Rh-­‐histidine	   6-­‐tagged	   TRAIL	   (114-­‐281)	   was	   produced	   in	   bacteria	   BL21,	   transformed	  with	   a	   pTrc-­‐His6	   TRAIL	   vector.	   The	   gene	   sequence	   (residues	   between	   114	   and	   281)	   was	  preceded	  by	  a	  histidine	  6-­‐tag	  and	  by	  a	  promoter	  that	  was	  stimulated	  by	  bacterial	   logarithmic	  phase	  growth.	  Protein	  extraction	  was	  performed	  by	  sonication	  and	  the	  use	  of	  different	  buffers,	  while	  purification	  was	  obtained	  by	  affinity	  chromatography	  on	  Ni2+	  affinity	  resin.	  Purification	  consisted	   of	   three	   steps:	   binding	   proteins	   to	   the	   Ni2+	   affinity	   resin,	   washing	   off	   unbound	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proteins,	   and	   eluting	   those	   purified.	   These	   purified	   preparations	   were	   then	   dialyzed	   for	   48	  hours	  in	  saline	  solution,	  aliquotated	  and	  stored	  at	  -­‐80°C.	  The	  Chromogenic	  Limulus	  Amebocyte	  Lysate	   (LAL)	   Test	   (BioWhittaker)	   was	   used	   to	   quantify	   bacterial	   endotoxins,	   which	   resulted	  always	   lower	   than	   0.1EU/ml.	   Then,	   the	   purity	   of	   each	   TRAIL	   preparation	   was	   evaluated	   by	  loading	   2	   μg	   of	   rh-­‐TRAIL	   in	   15%	   SDS-­‐PAGE	   (sodium	   dodecyl	   sulfate-­‐polyacrylamide	   gel	  electrophoresis),	   with	   or	   without	   β-­‐mercaptoethanol.	   The	   gels	   were	   then	   stained	   with	   the	  gelcode	   Silver	   SNAP	   Staining	   kit	   (Pierce,	   Boston,	   MA).	   Finally,	   TRAIL	   biological	   activity	   was	  determined	  in	  vitro	  by	  propidium	  iodide	  staining	  and	  flow	  cytometric	  analysis	  of	  apoptosis	  in	  the	  TRAIL-­‐sensitive	  HL-­‐60	  cell	  line.	  Rh-­‐	  his6-­‐TRAIL	  will	  be	  indicated	  as	  TRAIL	  throughout	  the	  text.	  	  	   	  
4.3	  Determination	  of	  body	  composition	  	  Total	   body	  mass,	   fat	  mass,	   and	   lean	  mass	  were	   evaluated	   at	   baseline,	   and	   every	   four	  weeks	  by	  EchoMRI	  (Echo	  Medical	  Systems,	  Houston	  Texas).	  	  
4.4	  Food	  intake	  and	  energy	  intake	  	  Food	   intake	   was	   measured	   every	   four	   weeks	   placing	   in	   the	   cages	   pellets	   previously	  weighed	  in	  total.	  The	  food	  that	  was	  left	  over	  was	  then	  collected	  and	  weighed	  to	  find	  the	  amount	  eaten.	  Energy	  intake	  was	  measured	  according	  to	  the	  digestible	  energy	  provided	  by	  both	  diets.	  	  
4.5	  Glucose,	  insulin,	  lipids,	  TRAIL	  and	  pro-­‐inflammatory	  cytokines	  measurements	  	  Glucose	  was	  measured	  using	  a	  glucometer	  (AccuCheck	  II;	  Roche,	  NSW,	  Australia)	  during	  the	   IPGTT,	   IPITT	   and	   at	   the	   end	   of	   the	   study,	   at	   fasting.	   Insulin	   was	   measured	   by	   ELISA	  (Millipore,	  Cat#	  EZRMI-­‐13K)	  during	  the	  IPGTT	  and	  at	  the	  end	  of	  the	  study,	  at	  fasting.	  The	  IPGTT	  was	   performed	   on	   day	   1	   after	   the	   last	   injection	   of	   TRAIL	   or	   saline.	   2g/kg	   of	   glucose	   were	  injected	  ip	  after	  an	  overnight	  fast	  and	  bloods	  were	  collected	  at	  baseline,	  15’,	  60’	  and	  120’	  after	  the	   injection.	   The	   IPITT	  was	   performed	   on	   day	   4	   after	   the	   last	   injection	   of	   TRAIL	   or	   saline.	  1U/kg	  of	  insulin	  was	  injected	  ip	  after	  a	  6	  hours	  fast	  and	  bloods	  were	  collected	  at	  baseline,	  15’,	  60’,	   and	   120’	   after	   the	   injection.	   At	   the	   end	   of	   the	   study,	   at	   fasting,	  we	   also	  measured:	   total	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cholesterol,	   LDL,	   HDL	   and	   triglycerides	   by	   COBAS	   INTEGRA	   200,	   FFAs	   by	   a	   colorimetric	   kit	  (Wako	   Pure	   Chemical	   Industries,	   Osaka,	   Japan)	   adiponectin	   and	   interleukin-­‐6	   (IL-­‐6),	  interleukin-­‐10	   (IL-­‐10),	   leptin,	   plasminogen	   activator	   inhibitor-­‐1	   (PAI-­‐1),	   monocyte	  chemoattractant	   protein-­‐1	   (MCP-­‐1),	   tumor	   necrosis	   factor	   α	   (TNF-­‐α)	   by	   Luminex	   with	   a	  commercial	   Multiplex	   kit	   (Millipore,	   Cat#MADPK-­‐71K	   and	   #MADPK-­‐71K-­‐ADPN).	   Circulating	  TRAIL	   was	   determined	   by	   ELISA	   (R&D	   Systems,	   Minneapolis,	   MN),	   as	   previously	   described	  [Campioni,	  2005].	  Sensitivity	  of	  the	  TRAIL	  assay	  was	  2.9	  pg/ml	  and	  the	  intra-­‐	  and	  inter-­‐	  assay	  coefficients	  of	  variation	  (CV)	  were	  3.9%	  and	  6%,	  respectively.	  	  
4.6	  Indirect	  calorimetry	  studies	  	  O2	   consumption	   rate	   (V02)	   and	  CO2	  production	   rate	   (VCO2)	  were	  determined	  before	  the	   last	   injection	   of	   TRAIL	   by	   indirect	   calorimetry	   (Oxymax,	   Columbus	   Instruments),	   with	   1	  mouse	   per	   chamber.	   Each	   chamber	  was	   equipped	  with	   a	   3-­‐dimensional	   (xyz)	   infrared	   beam	  system	   (OPTO-­‐	   M3)	   to	   record	   locomotor	   activity.	   Conditioned	   fresh	   air	   at	   21±0.5oC	   and	  55%±5%	   relative	   humidity	   was	   pumped	   into	   the	   chambers	   at	   0.6	   l/min.	   The	   animals	   were	  acclimated	   to	   the	   chambers	   for	   1	   day,	   and	   VO2	   and	   VCO2	   measurements	   taken	   every	   30	  minutes	  were	   collected	   and	   recorded	  on	   a	   computer	   over	   the	   next	   24	  hours.	  During	   the	   12-­‐hours	   dark/12-­‐hours	   light	   phases,	   mice	   had	   free	   access	   to	   food	   and	   water.	   The	   energy	  expenditure	  was	  expressed	  as	  VO2.	  RER	  was	  calculated	  as	  VCO2	  production/VO2	  consumption,	  with	  the	  values	  of	  1	  or	  0.7	  indicating	  100%	  CHO	  or	  100%	  fat	  oxidation,	  respectively.	  	  
4.7	  Palmitate	  oxidation	  rate	  	   At	  the	  end	  of	  the	  study,	  to	  evaluate	  FFA	  oxidation	  rate	  in	  the	  skeletal	  muscle	  of	  the	  mice	  studied,	   palmitate	   oxidation	   rate	   was	   measured	   in	   skeletal	   muscle	   homogenates	   using	   a	  modified	   method	   described	   by	   Turner	   and	   associates	   [Turner,	   2007].	   Muscles	   were	  homogenized	  in	  19	  volumes	  of	  ice-­‐cold	  250	  mmol/l	  sucrose,	  10	  mmol/l	  Tris-­‐HCl,	  and	  1	  mmol/l	  EDTA,	   pH	   7.4.	   For	   assessment	   of	   substrate	   oxidation,	   50	   μl	   of	   muscle	   homogenate	   was	  incubated	  with	  450	  μl	  reaction	  mixture	  (pH	  7.4).	  Final	  concentrations	  of	  the	  reaction	  mixture	  were	  (in	  mmol/l):	  100	  sucrose,	  80	  KCl,	  10	  Tris-­‐	  HCl,	  5KH2PO4,	  1	  MgCl2,	  2	  malate,	  2	  ATP,	  1	  DTT,	  0.2	  EDTA	  and	  0.3%	  FFA	  free	  BSA.	  Substrates	  were	  0.2	  mmol/l	  [1-­‐14C]palmitate	  (0.5	  μCi)	  plus	  2	  mmol/l	  carnitine	  and	  0.05	  mmol/l	  coenzyme	  A.	  After	  90	  min	  of	  incubation	  at	  30°C,	  the	  reaction	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was	  stopped	  by	  the	  addition	  of	  100	  μL	  of	  ice-­‐cold	  1	  mol/l	  perchloric	  acid.	  CO2	  produced	  during	  the	  incubation	  was	  collected	  in	  100	  μl	  of	  1	  mol/l	  sodium	  hydroxide.	  14C	  counts	  present	  in	  the	  acid-­‐soluble	   fraction	  were	  also	  measured	  and	  combined	  with	  the	  CO2	  values	  to	  give	  the	  total	  palmitate	  oxidation	  rate.	  	  
4.8	  Gene	  expression	  quantification	  by	  Real-­‐time	  PCR	  	  Three	  micrograms	  of	  total	  RNA	  extracted	  from	  adipose	  tissue,	  liver,	  and	  skeletal	  muscle	  were	   used	   to	   synthesize	   cDNA	   with	   Superscript	   First	   Strand	   synthesis	   system	   for	   RT-­‐PCR	  (Gibco	  BRL).	  Bcl-­‐2,	   caspase3,	   IL-­‐6,	  MCP-­‐1,	  and	  TNF-­‐α	  gene	  expression	  were	  analysed	  by	  real-­‐time	   quantitative	   RT-­‐PCR	   using	   the	   TaqMan	   system	   based	   on	   real-­‐time	   detection	   of	  accumulated	   fluorescence.	  Fluorescence	   for	  each	  cycle	  was	  quantitatively	  analysed	  by	  an	  ABI	  Prism	   7700	   Sequence	   Detection	   System	   (Perkin-­‐Elmer	   Inc).	   Gene	   expression	   of	   the	   target	  sequence	  was	  normalized	  in	  relation	  to	  the	  expression	  of	  an	  endogenous	  control,	  18s	  ribosomal	  RNA.	  Primers	  and	  Taqman	  probes	  were	  constructed	  with	  the	  help	  of	  Primer	  Express	  (ABI	  Prism	  
7700,	  Perkin-­‐Elmer	  Inc).	  	  
4.9	  In	  vivo	  apoptosis	  	  Adipose	   tissue	   apoptosis	   was	   detected	   by	   Transferase-­‐mediated	   dUTP	   Nick	   End	  Labeling	   (TUNEL)	   staining.	  Apoptosis	  was	   identified	  by	  3’	   in	   situ	   end	   labeling	  of	   fragmented	  DNA	   with	   Terminal	   deoxynucleotidyltransferase	   (TdT).	   After	   fixation	   and	   permeabilisation	  with	   0.1%	   Triton	   X-­‐100	   and	   0.1%	   sodium	   citrate	   fresh	   solution,	   20	   μm	   frozen	   sections	   of	  adipose	  tissue	  were	  incubated	  with	  TUNEL	  reaction	  mixture,	  according	  to	  the	  manufacturer’s	  instructions	   (Roche	   diagnostic,	   Indianapolis,	   IN)	   and	   mounted	   with	   DAPI	   to	   be	   seen	   under	  fluorescence.	   The	   number	   of	   (TUNEL)-­‐positive	   cells	   was	   calculated	   and	   expressed	   as	  percentage	  of	  TUNEL-­‐positive	  cells	  per	  frame.	  	  
4.10	  Statistical	  analysis	  	  Data	  were	  calculated	  and	  shown	  as	  means	  ±	  standard	  errors	  of	  the	  mean.	  Comparisons	  between	  STZ-­‐treated	  animals	  and	  normal	  controls	  were	  performed	  with	  Student	  t	  test	  and	  with	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5.1.	  TRAIL	  significantly	  reduces	  the	  increased	  adiposity	  associated	  with	  a	  high	  fat	  diet	  in	  
spite	  of	  promoting	  a	  higher	  energy	  intake	  	   C57	  HF	  mice	  became	  obese	  (Figure	  4A)	  and	  displayed	  increased	  adiposity	  after	  4,	  8	  and	  12	  weeks	  compared	  to	  C57	  chow	  mice	  (Figure	  4B).	  The	  increase	  in	  adiposity	  due	  to	  a	  HFD	  was	  significantly	  delayed	  by	  TRAIL	  treatment.	  After	  4	  weeks	  of	  study,	  C57	  HF	  +	  TRAIL	  mice	  did	  not	  differ	  from	  C57	  chow	  mice	  in	  terms	  of	  adiposity,	  whereas	  their	  fat	  mass	  was	  significantly	  lower	  than	   the	   fat	   mass	   of	   C57	   HF	   untreated.	   After	   8	   and	   12	   weeks	   of	   study	   TRAIL	   significantly	  reduced	  the	  adiposity	  of	  the	  mice	  high	  fat	  fed	  (Figure	  4B).	  There	  was	  no	  significant	  difference	  in	  terms	  of	   lean	  mass	  between	  the	  groups	  studied	  (Figure	  4C).	  C57	  HF	  mice	  ate	  significantly	  less	  (p	  <	  0.05)	  than	  the	  other	  mice	  groups	  during	  the	  length	  of	  the	  study.	  Given	  the	  composition	  of	  both	  diets,	  C57	  HF+TRAIL	  mice	  displayed	  the	  highest	  energy	  intake	  among	  the	  groups,	  eating	  0.094±0.006	  mj/day,	   compared	   to	   C57	   chow	  mice,	   eating	   0.057±0.004	  mj/day,	   and	   C57	   HF,	  eating	  0.06±0.004	  mj/day	  (p<0.05	  vs	  both	  C57	  chow	  and	  C57	  HF+TRAIL).	  It	  is	  noteworthy	  that	  repeated	   ip	   injections	   of	   TRAIL	  were	   safe,	   since	  mice	   treated	  with	   TRAIL	   didn’t	   show	   gross	  abnormalities	   at	   necroscopic	   examination	  with	   respect	   to	   the	  mock	   treated	  mice.	  Moreover,	  human	   TRAIL	   was	   detectable	   by	   ELISA	   in	   sera	   of	   the	   injected	   mice	   up	   to	   4	   days	   after	   ip	  injections	  (data	  not	  shown).	  
	  
5.2.	  TRAIL	  significantly	  reduces	  hyperglycaemia	  and	  hyperisulinemia	  during	  an	  IPGTT	  as	  
well	  as	  hyperinsulinemia	  at	  fasting	  and	  improves	  the	  peripheral	  response	  to	  insulin	  in	  high	  
fat	  fed	  mice	  	  	  The	  IPGTT	  (Figure	  5A)	  showed	  that	  the	  HFD	  resulted	  in	  a	  significant	  impairment	  of	  glucose	   clearance,	   leading	   to	   hyperglycemia	   at	   all	   the	   time-­‐points	   examined,	   which	   was	  significantly	  reduced	  by	  TRAIL	  at	  all	  the	  time-­‐points	  (Figure	  5A).	  The	  area	  under	  the	  curve	  was	  1291.08±240.58	   in	   C57	   chow	   mice,	   2744.25±152.72	   in	   C57	   HF	   (p<0.05	   vs	   C57	   chow)	   and	  2277.9±186.13	   in	   C57	   HF+TRAIL	   (p<0,01	   vs	   C57	   HF).	   As	   for	   insulin	   levels	   during	   the	   same	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IPGTT	   (Figure	   5B),	   C57	  HF	  mice	   displayed	   a	   significant	   hyperinsulinemia	   compared	   to	   C57	  chow	  mice,	  which	  was	  significantly	  reduced	  by	  TRAIL	  treatment	  (Figure	  5B).	  The	  area	  under	  the	  curve	  was	  152.44±1.87	  in	  C57	  chow	  mice,	  278.15±24.52	  in	  C57	  HF	  (p<0.05	  vs	  C57	  chow)	  and	   160.50±17.13	   in	   C57	   HF+TRAIL	   (p<0.01	   vs	   C57	   HF).	   The	   IPITT	   showed	   that	   TRAIL	  treatment	   improved	   the	   peripheral	   response	   to	   insulin	   in	   mice	   fed	   a	   HFD,	   lowering	   their	  glucose	   levels	   (C57	   HF+TRAIL	   vs	   C57+HF)	   at	   all	   time-­‐points	   examined	   and	   reaching	   the	  significance	  at	  60	  and	  120	  minutes	  after	   the	   insulin	  challenge	   (Figure	   5C).	  At	   the	  end	  of	   the	  study,	  although	  glucose	  levels	  were	  not	  significantly	  lower	  in	  C57	  HF+TRAIL	  mice	  compared	  to	  the	  mice	  untreated,	  C57	  HF+TRAIL	  mice	  presented	  lower	   levels	  of	   insulin	  at	   fasting	  than	  C57	  HF	  mice	  (Figure	  5D).	  Serum	  total	  cholesterol,	  HDL	  and	  LDL	  increased	  after	  HFD	  without	  being	  affected	  by	  TRAIL	  treatment	  (p<0.001	  vs	  C57	  chow).	  Nor	  serum	  tryglicerides	  nor	  free	  fatty	  acid	  change	  among	  the	  groups	  being	  0.59±0.09	  mmol/Lin	  C57	  chow	  mice;	  0.61±0.19	  mmol/L	  in	  C57	  HF	  mice	  and	  0.58±0.225	  mmol/L	  in	  C57	  HF	  TRAIL.	  
	  
5.3.	  TRAIL	  treatment	  significantly	  reverses	  the	  changes	  in	  substrate	  utilization	  induced	  by	  
HFD	  and	  ameliorates	  ex	  vivo	  palmitate	  oxidation	  	   At	  the	  end	  of	  the	  study,	  indirect	  calorimetry	  showed	  that	  the	  VO2	  increased	  significantly	  after	   a	   HFD	   (Table	   5).	   Heat	   production	   increased	   in	   both	   C57	   HF	   and	   C57	   HF+TRAIL	  mice	  compared	  to	  the	  controls,	  whereas	  locomotor	  activity	  was	  significantly	  reduced	  in	  the	  C57	  HF	  mice.	  Interestingly,	  the	  measurement	  of	  the	  respiratory	  exchange	  ratio	  (RER),	  which	  is	  the	  ratio	  between	  VCO2	  produced	  and	  VO2	  burnt,	   showed	   that	   followed	  a	  HFD	   significantly	   shifts	   the	  metabolism	  towards	  a	  nearly	  complete	  fat	  consumption	  as	  fuel,	  as	  the	  C57	  HF	  mice	  displayed	  a	  RER	  significantly	  lower	  than	  the	  RER	  of	  the	  controls	  (Table	  5).	  TRAIL	  significantly	  reversed	  the	  reduction	   of	   the	   RER	   that	   follows	   a	   HFD	   as	   the	   C57	   HF+TRAIL	   mice	   displayed	   an	   RER	  significantly	   higher	   than	   the	  RER	  of	   the	  C57	  HF	  mice	   (Table	   5).	   In	   parallel	   experiments,	  we	  found	   that	   ex	   vivo	  palmitate	   oxidation	   (nmol/min/g)	   in	   skeletal	   muscle,	   measured	   after	   12	  weeks	   of	   HFD,	   significantly	   increased	   in	   C57	   HF	   vs	   C57	   chow	   (16.56±1.1	   vs	   14.3±1.1,	  respectively,	   p<0.05).	   However,	   TRAIL	   treatment	   further	   increased	   it	   compared	   to	   C57	   HF	  (19.53±1.8	  vs	  16.56±1.1,	  respectively,	  p<0.05).	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  5.04	  ±	  0.31	  	   	  6.40	  ±	  0.23	  *	  	   	  6.6	  ±	  0.42	  *	  	  
Heat	  (Kcal/HR) 
	  0.56	  ±	  0.01	  
 
0.72	  ±	  0.03	  * 0.81	  ±	  0.03	  * 
Locomotor	  activity 
	  21074	  ±	  1365	  
 
15077	  ±	  861	  * 24468	  ±	  2055	  # 
RER	  (VCO2/VO2) 
	  0.89	  ±	  0.01	  
 
0.77±	  0.007	  * 0.82	  ±	  0.0009	  *# 
Palmitate	  oxidation	  
(nmol/min/g)	   14.4±1.1	   16.56±1.1	  
	  	  19.53±1.8	  	   	  All	  the	  data	  are	  expressed	  as	  mean	  ±	  SEM;	  *	  p	  <	  0.05	  vs	  C57	  chow;	  #	  p	  <	  0.05	  vs	  C57	  HF.	  	  C57bl6	  mice	  allocated	  to	  high	  fat	  diet	  (C57	  HF);	  C57bl6	  mice	  allocated	  to	  high	  fat	  diet	  +	  TRAIL	  (C57	  HF	  +	  TRAIL);	  High	  fat	  (HF);	  Respiratory	  exchange	  ratio	  (RER);	  Tumor	  necrosis	  factor-­‐related	  apoptosis-­‐inducing	  ligand	  (TRAIL).	  (Adapted	  from	  Bernardi,	  2012c)	  	  
5.4.	  TRAIL	  significantly	  lowers	  circulating	  levels	  and	  gene	  expression	  of	  pro-­‐inflammatory	  
cytokines	  	   As	   for	   the	   circulating	   levels	   of	   the	   adipokines	   measured,	   adiponectin	   decreased	  significantly	   in	   the	   mice	   high	   fat	   fed	   with	   respect	   to	   the	   controls	   but	   it	   did	   not	   change	  significantly	  after	  TRAIL	   treatment.	  Adiponectin	   levels	  were	   respectively	  11±1	  μg/mL	   in	  C57	  chow,	  7±1	  μg/mL	   in	  C57	  HF,	  9±1	  μg/mL	   in	  C57	  HF	  +	  TRAIL	  mice.	   Leptin	   levels	   also	  did	  not	  change	  between	  the	  C57	  HF	  and	  C57	  HF	  +	  TRAIL	  mice,	  being	  1350±248	  pg/mL	  in	  C57	  chow,	  12959±1381	  pg/mL	  in	  C57	  HF	  and	  10909±1418	  pg/mL	  in	  C57	  HF+TRAIL	  mice.	  Among	   the	   cytokines	   measured,	   IL-­‐6	   increased	   significantly	   in	   C57	   HF	   mice	   and	   was	  significantly	  reduced	  by	  TRAIL	  (Figure	  6A).	  IL-­‐10	  did	  not	  change	  between	  the	  groups	  studied,	  being	  26±14	  pg/mL	  in	  C57	  chow,	  37±10	  pg/mL	  in	  C57	  HF	  and	  20±12	  pg/mL	  in	  C57	  HF	  +	  TRAIL	  mice.	   MCP-­‐1	   followed	   the	   same	   trend	   of	   IL-­‐6,	   being	   570±328	   pg/mL	   in	   C57	   chow	   mice,	  1750±1559	   pg/mL	   in	   C57	   HF	  mice	   and	   300±222	   pg/mL	   in	   C57	   HF+TRAIL	  mice.	   PAI-­‐1	  was	  1326±264	   pg/mL	   in	   C57	   chow;	   1593±198	   pg/mL	   in	   C57	   HF	   and	   1332±214	   pg/mL	   in	   C57	  HF+TRAIL	  mice.	  TNF-­‐α	  levels	  followed	  the	  same	  trend	  of	  IL-­‐6	  (Figure	  6B).	  This	  was	  consistent	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with	   the	   significant	   reduction	   of	   hepatic	   IL-­‐6	   gene	   expression	   as	  well	   as	  with	   the	   significant	  downregulation	   of	   TNF-­‐α	   in	   adipose	   tissue	   and	   skeletal	   muscle,	   which	   were	   observed	   after	  TRAIL	  treatment	  (Figure	  7).	  A	  significant	  downregulation	  of	  MCP-­‐1	  in	  adipose	  tissue	  was	  also	  observed	  (Table	  6)	  
	  
5.5.	  TRAIL	  treatment	  modulates	  adipose	  tissue	  gene	  expression	  and	  promotes	  adipose	  
tissue	  apoptosis	  	  Apart	  from	  IL-­‐6	  and	  TNF-­‐α,	  the	  expression	  of	  genes	  related	  to	  apoptosis,	  such	  as	  Bcl-­‐2	  and	  caspase3	  was	  analyzed.	  As	  summarized	  in	  Table	  6,	  TRAIL	  treatment	  was	  associated	  with	  a	  significant	   up-­‐regulation	   of	   caspase-­‐3.	   Consistent	  with	   this	   induction,	   TRAIL	   treated	   C57	  HF	  mice	  displayed	  a	  significant	  increase	  (average	  2.8	  fold;	  p<0.001)	  of	  the	  percentage	  of	  apoptotic	  cells	  in	  adipose	  tissue	  sections.	  	  






C57	  chow	   C57	  HF	   C57	  HF	  +	  trail	  
Bcl-­‐2	  
	  1	  ±	  0.29	  	   5.80	  ±	  1.58	  *	   4.21	  ±	  0.47	  *	  
Caspase-­‐3	  
	  1	  ±	  0.25	  	   1.96	  ±	  0.32	  *	   	  3.91	  ±	  0.60	  *#	  	  
IL-­‐6	  




1	  ±	  0.16	   5.26	  ±	  1.34	   2.4	  ±	  0.42	  *#	  
PPARγ	  
	  1	  ±	  0.12	  	   	  5.93	  ±	  2.12	  *	  	   	  2.04	  ±	  0.17	  *	  	  
	  
TNF-­‐α	  	   	  1	  ±	  0.28	  	   	  3.82	  ±	  0.91	  *	  	   	  1.02	  ±	  0.20	  #	  	  Adipose	  tissue	  mRNA	  expression	  of	  Bcl-­‐2,	  BMP-­‐7,	  Caspase-­‐3,	  IL-­‐6,	  PPARγ,	  TNF-­‐α	  in	  C57	  chow,	  C57	  HF,	  C57	  HF	  +	  TRAIL	  mice.	  mRNA	  expression	  is	  reported	  as	  relative	  gene	  units;	  data	  is	  expressed	  as	  mean	  ±	  SEM.	  *	  p	  <	  0.05	  vs	  C57	  chow;	  #	  p	  <	  0.05	  vs	  C57	  HF.	  B-­‐cell	  lymphoma	  2	  (BCL2);	  Bone	  morphogenetic	  protein	  7	  (BMP7);	  C57bl6	  mice	  allocated	  to	  high	  fat	  diet	  (C57	  HF);	  C57bl6	  mice	  allocated	  to	  high	  fat	  diet	  +	  TRAIL	  (C57	  HF	  +	  TRAIL);	  High	  fat	  (HF);	  Interleukin-­‐6	  (IL-­‐6);	  Monocyte	  chemoattractant	  protein-­‐1	  (MCP-­‐1);	  Peroxisome	  proliferator	  activated	  receptorγ	  (PPARγ);	  Tumor	  necrosis	  factor-­‐α	  (TNF-­‐α);	  Tumor	  necrosis	  factor-­‐related	  apoptosis-­‐inducing	  ligand	  (TRAIL).	  (Adapted	  from	  Bernardi,	  2012c)	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Figure	  4.	  Body	  mass	  composition	  	  (A)	  Total	  mass	  (g)	  at	  baseline,	  4,	  8	  and	  12	  weeks	  of	  study;	  (B)	  Fat	  mass	  (g)	  at	  baseline,	  4,	  8	  and	  12	  weeks	  of	  study;	  (C)	  Lean	  mass	  (g)	  at	  baseline,	  4,	  8	  and	  12	  weeks	  of	  study.	  Data	  is	  expressed	  as	  means±SEM.	  *	  p<0.05	  C57	  HF	  vs	  C57	  chow;	  #	  p<0.05	  C57	  HF	  vs	  C57	  HF+TRAIL.	  C57bl6	  mice	  allocated	  to	  standard	  chow	  diet	  (C57	  chow);	  C57bl6	  mice	  allocated	  to	  high	  fat	  diet	  (C57	  HF);	  C57bl6	  mice	  allocated	  to	  high	  fat	  diet+TRAIL	  (C57	  HF+TRAIL);	  High	  fat	  (HF);	  Tumor	  necrosis	  factor	  –related	  apoptosis-­‐inducing	  ligand	  (TRAIL).	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Figure	  5.	  Glucose	  and	  insulin	  levels.	  (A)	  Blood	  glucose	  (mmol/L)	  during	  an	  IPGTT	  at	  0’,	  15’,	  60’,	  120’;;	  (B)	  Serum	  insulin	   (ng/mL)	  during	   an	   IPGTT	  at	  0’,	   15’,	   60’,	   120’;;	   (C)	  Blood	  glucose	   (mmol/L)	  during	   an	   IPITT	  at	  0’,	   30’,	   60’,	   120’;;	   (D)	  Plasmatic	  insulin	  (ng/mL)	  at	  fasting.	  Data	  is	  expressed	  as	  mean	  ±	  SEM;	  *	  p<0.05	  C57	  HF	  vs	  C57	  chow;	  #	  p<0.05	  C57	  HF	  vs	  C57	  HF+TRAIL.	  C57bl6	  mice	  allocated	  to	  standard	  chow	  diet	  (C57	  chow);	  C57bl6	  mice	  allocated	  to	  high	  fat	  diet	  (C57	  HF);	  C57bl6	  mice	   allocated	   to	   high	   fat	   diet	   +	   TRAIL	   (C57	   HF	   +	   TRAIL);	   Intraperitoneal	   glucose	   tolerance	   test	   (IPGTT);	   Intraperitoneal	  insulin	  tolerance	  test	  (IPITT);	  High	  fat	  (HF);	  Tumor	  necrosis	  factor-­‐related	  apoptosis-­‐inducing	  ligand	  (TRAIL).	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Figure	   6.	  Circulating	   levels	   of	   pro-­‐inflammatory	   cytokines.	  Plasmatic	   levels	  of	   IL-­‐6	  and	  TNF-­‐α	   in	  C57	  chow,	  C57	  HF	  and	  C57	  HF+TRAIL	  mice.	  IL-­‐6	  and	  TNF-­‐α	  are	  measured	  as	  pg/mL.	  Data	  is	  expressed	  as	  means±SEM;	  *p<0.05	  C57	  HF	  vs	  C57	  chow;	  #	  p<0.05	  C57	  HF	  vs	  C57	  HF+TRAIL.	  C57bl6	  mice	  allocated	  to	  high	  fat	  diet	  (C57	  HF);	  C57bl6	  mice	  allocated	  to	  high	  fat	  diet+TRAIL	  (C57	  HF	  +	  TRAIL);	  high	  fat	  (HF);	   Interleukin-­‐6	  (IL-­‐6);	  Tumor	  necrosis	   factor-­‐related	  apoptosis-­‐	   inducing	  ligand	  (TRAIL);	  Tumor	  necrosis	  factor-­‐α	  (TNF-­‐α).	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Figure	   7.	   Gene	   expression	   of	   pro-­‐inflammatory	   cytokines.	   (A)	   Adipose,	   hepatic	   and	  muscular	  mRNA	  expression	  of	  IL-­‐6	  and	  TNF-­‐α	  in	  C57	  chow,	  C57	  HF	  and	  C57	  HF	  +	  TRAIL	  mice.	  mRNA	  expression	  is	  reported	  as	  relative	  gene	  units;	  data	  is	  expressed	  as	  mean	  ±	  SEM.	  *	  p	  <	  0.05	  C57	  HF	  vs	  C57	  chow;	  #	  p	  <	  0.05	  C57	  HF	  +	  TRAIL	  vs	  C57	  HF.	  C57bl6	  mice	  allocated	   to	   high	   fat	   diet	   (C57	  HF);	   C57bl6	  mice	   allocated	   to	   high	   fat	   diet	   +	   TRAIL	   (C57	  HF	   +	   TRAIL);	   high	   fat	   (HF);	   tumor	  necrosis	  factor-­‐related	  apoptosis-­‐inducing	  ligand	  (TRAIL);	  Interleukin-­‐6	  (IL-­‐6);	  Tumor	  necrosis	  factor-­‐α	  (TNF-­‐α).	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Discussion	  
	   It	  has	  been	  demonstrated	  that	  HFD-­‐fed	  C57Bl6	  mice	  develop	  a	  significant	  impairment	  in	  glucose	  tolerance	  and	  a	  40%	  reduction	  in	  insulin	  stimulated	  glucose	  uptake	  in	  skeletal	  muscle	  [Turner,	  2007].	  This	  relies	  on	  the	  notion	  that	  an	  oversupply	  of	  lipids,	  leading	  to	  an	  abnormal	  accumulation	   of	   fat	   in	   adipose	   and	   non-­‐adipose	   tissues	   such	   as	   muscle	   and	   liver,	   plays	   an	  important	  role	   in	   the	  etiology	  of	   insulin	  resistance	  and	   later	  on	   in	   the	  demise	  of	   the	  β-­‐cell	   in	  T2DM	   [McGarry,	   2002].	   TRAIL	   deficiency	   has	   recently	   been	   found	   to	   promote	   numerous	  features	  of	  T2DM	  in	  mice	  high	  fat	  fed.	  In	  our	  work,	  whose	  aim	  was	  the	  study	  of	  the	  effects	  of	  TRAIL	  delivery	  in	  mice	  high	  fat	  fed,	  we	  have	  documented	  the	  ability	  of	  recombinant	  TRAIL	  to	  significantly	   reverse	   the	  metabolic	   abnormalities	   due	   to	   an	   oversupply	   of	   lipids	   and	   thus	   to	  slow	   down	   the	   natural	   history	   of	   T2DM.	   TRAIL	   treatment	   reduced	   significantly	   the	  hyperglycemia	   and	   the	   hyperinsulinemia	   displayed	   by	   high	   fat	   fed	   mice	   during	   an	   IPGTT.	  Consistent	   with	   this,	   TRAIL	   treatment	   ameliorated	   their	   peripheral	   response	   to	   insulin,	  lowering	  significantly	  glucose	  levels	  during	  an	  IPITT.	  	  An	  increased	  utilization	  of	  free	  fatty	  acid	  for	  fuel	  in	  skeletal	  muscle	  is	  a	  typical	  feature	  of	  HFD-­‐related	  insulin	  resistance	  [Turner,	  2007].	  This	  phenomenon	  has	  been	  explained	  either	  as	  a	   compensatory	   response	   to	   a	   greater	   availability	   of	   fatty	   acids	   substrates	   or	   as	   the	  consequence	   of	   an	   abnormal	   peripheral	   response	   to	   insulin,	   so	   that	   the	   body	   cannot	   burn	  glucose	   efficiently.	   As	   expected,	   in	   our	   study,	   C57	   HF	   mice	   shifted	   their	   metabolism	   from	  glucose	   towards	   lipids	   consumption,	   according	   to	   their	   lower	   RER	   and	   increased	   skeletal	  muscle	  palmitate	  oxidation	  rate.	  TRAIL	  treatment	  was	  associated	  with	  an	  improvement	  of	  the	  peripheral	  response	  to	  insulin	  and	  an	  increased	  RER.	  Quite	  surprisingly	  though,	  skeletal	  muscle	  palmitate	   oxidation	   rate	   was	   significantly	   higher	   in	   C57	   HF+TRAIL	  mice	   compared	   to	   those	  untreated.	  To	  clarify	  this	  data	  two	  aspects	  should	  be	  taken	  into	  account.	  Firstly,	  any	  muscular	  lipid	   overload	  may	   be	   linked	   to	   a	   reduction	   in	   lean	  mass,	   as	   it	   is	   seen	   in	   insulin	   resistance,	  which	   in	   turn	  would	   lead	   to	   low	  rates	  of	  palmitate	   (or	  FFAs)	  oxidation.	  Secondly,	   the	  ex	  vivo	  assessment	  of	  FFA	  oxidation	  is	  performed	  under	  favourable	  conditions	  of	  substrate	  availability	  in	   an	   environment	   free	   of	   regulatory	   factors	   that	   might	   affect	   this	   process	   [Turner,	   2007].	  However,	  since	  mitochondrial	  dysfunction	  has	  been	  pointed	  out	  as	  one	  of	   the	  earliest	  defects	  that	  predispose	  to	  lipid	  accumulation	  and	  insulin	  resistance,	  the	  increased	  palmitate	  oxidation	  
 45 
rate	  observed	  in	  high	  fat	   fed	  mice	  treated	  with	  TRAIL	  is	  consistent	  with	  a	  protective	  effect	  of	  TRAIL	   against	   mithocondrial	   dysfunction	   and	   therefore	   lipid	   accumulation	   and	   insulin	  resistance.	  	  The	   reversal	   of	   the	  metabolic	   abnormalities	   due	   to	   a	  HFD	  upon	  TRAIL	   treatment	  was	  accompanied	  by	  the	  effect	  of	  TRAIL	  on	  mice	  adiposity.	  TRAIL	  treatment	  significantly	  reduced	  the	  deposition	  of	  fat	  mass	  induced	  by	  the	  HFD	  during	  the	  length	  of	  the	  study.	  This	  is	  consistent	  with	  what	  has	  been	  reported	  by	  Di	  Bartolo	  and	  colleagues	  [Di	  Bartolo,	  2011],	  who	  found	  that	  mice	   lacking	   TRAIL	   presented	   an	   increased	   deposition	   of	   fat.	   A	   different	   group	   has	   recently	  reported	   an	   association	   between	   serum	   TRAIL	   concentrations,	   serum	   lipid	   levels	   and	   body	  adiposity	   in	   healthy	   adults	   [Choi,	   2004].	   In	   this	   cohort,	   TRAIL	   serum	   concentrations	   were	  shown	   to	   increase	   proportionally	   with	   the	   body	   mass	   and	   circulating	   lipids	   levels.	   So	   it	   is	  conceivable,	  that	  TRAIL,	  which	  has	  been	  shown	  to	  counteract	  fat	  accumulation,	  increases	  as	  the	  body	  mass	  increases	  because	  of	  a	  compensatory	  mechanism	  set	  up	  by	  the	  body	  to	  respond	  to	  fat	  gain.	  In	  our	  work,	  the	  significant	  reduction	  in	  the	  adiposity	  gained	  after	  a	  HFD	  that	  followed	  TRAIL	   delivery	   was	   not	   due	   to	   a	   reduction	   in	   food	   intake	   or	   to	   a	   change	   in	   circulating	  adiponectin	  and	  leptin.	  On	  the	  contrary,	  our	  data	  shows	  that	  C57	  HF+TRAIL	  mice	  ate	  as	  much	  as	  C57	  chow	  mice,	  whereas	  C57	  HF	  mice	  displayed	  a	   reduction	   in	   their	   food	   intake,	  possibly	  related	  to	  the	  increased	  adiposity	  which	  would	  have	  lead	  them	  to	  move	  less	  for	  seeking	  food.	  Since	   the	   HFD	   is	   slightly	   hypercaloric	   compared	   to	   the	   standard	   diet,	   C57	   HF+TRAIL	   mice	  displayed	  the	  highest	  caloric	  intake	  during	  the	  length	  of	  the	  study.	  	  The	  analyses	  performed	  on	  the	  fat	  of	  the	  mice	  suggest	  an	  effect	  of	  TRAIL	  on	  fat	  apoptosis	  and	   differentiation.	   TRAIL	   best	   known	   function	   is	   indeed	   the	   induction	   of	   apoptosis,	   which	  occurs	   through	   the	   activation	   of	   the	   extrinsic	   apoptotic	   pathway	   and	   a	   cross-­‐talk	   between	  extrinsic	   and	   intrinsic	   pathways,	   triggered	   by	   the	   binding	   of	   a	   soluble	   TRAIL	   trimer	   to	   its	  receptors	   TRAIL-­‐R1	   and	   TRAIL-­‐R2	   [Bernardi,	   2012a].	   This	   effect	   is	   selective,	   so	   whereas	  activated	  or	  transformed	  cells	  are	  sensitive	  to	  TRAIL-­‐induced	  apoptosis,	  non-­‐transformed	  cells	  are	  generally	  not	  affected	  by	   it	   [Bernardi,	  2012a].	  However,	  a	  recent	  work	  has	  shed	   light	  on	  the	  ability	  of	  TRAIL	  to	  induce	  apoptosis	  of	  human	  pre-­‐adipocytes	  [Mader,	  2012].	  In	  this	  work,	  apoptosis	   was	   caused	   by	   a	   synergistic	   interaction	   between	   resveratrol	   and	   TRAIL,	   which	  activated	   the	   intrinsic	   apoptosis	  pathway,	   and	   caspases.	  Here,	  we	   found	  an	  up-­‐	   regulation	  of	  caspase-­‐3	  as	  well	  as	  an	   increase	  of	  apoptotic	  nuclei	  within	  the	  adipose	  tissue	  of	  mice	  treated	  with	  TRAIL.	  So,	  a	  possible	  mechanism	  underlying	  the	  reduction	  of	  fat	  mass	  by	  TRAIL	  treatment	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could	   be	   a	   pro-­‐apoptotic	   effect	   against	   pre-­‐adipocytes.	   However,	   there	   may	   be	   other	  mechanisms	   underlying	   our	   observations,	   such	   as	   an	   effect	   of	   TRAIL	   on	   adipocyte	  differentiation,	  which	   has	   recently	   been	   reported	   by	  Keuper	   and	   colleagues	   [Keuper,	   2011].	  Consistent	  with	  this,	  in	  our	  study,	  TRAIL	  treatment	  significantly	  downregulated	  PPARγ,	  a	  well	  known	  regulator	  of	  adipogenesis	  and	  neutral	  lipid	  storage,	  which	  induces	  fat	  cell	  differentiation	  [Lehrke,	  2005].	  	  The	  improvement	  of	  T2DM	  metabolic	  abnormalities	  following	  TRAIL	  treatment	  could	  be	  explained	   with	   its	   effect	   on	   adiposity,	   which	   might	   then	   have	   influenced	   pro-­‐inflammatory	  cytokines	  levels	  and	  glucose	  metabolism.	  It	  is	  in	  fact	  well	  known	  that	  obesity	  is	  an	  independent	  predictor	   of	   insulin	   resistance	   and	   T2DM	   [Collins,	   2011].	   Clinical	   studies	   as	   the	   Finnish	  Diabetes	   Prevention	   Study	   [Tuomilheto,	  2001]	   have	   shown	   that	   T2DM	   can	   be	   prevented	   by	  lifestyle	  modifications	  leading	  to	  weight	  loss.	  Among	  the	  multiple	  mechanisms	  linking	  obesity	  to	  diabetes,	  inflammation	  is	  a	  common	  feature	  that	  has	  been	  implicated	  in	  the	  pathophysiology	  of	  both	  diseases.	  Several	  evidences	  have	  in	  fact	  proven	  the	  existence	  of	  an	  association	  between	  obesity,	   low-­‐grade	   inflammation	   and	   metabolic	   disturbances	   such	   as	   insulin	   resistance	   and	  T2DM	   [Xu,	   2003].	   For	   instance,	   weight	   loss	   was	   able	   to	   reduce	   inflammatory	   markers	  [Esposito,	   2003;	   Bastard,	   2000]	   with	   an	   improvement	   of	   insulin	   sensitivity	   [Ryan,	   1994],	  whereas	   the	   deficiency	   of	   pro-­‐inflammatory	   cytokines,	   such	   as	   TNF-­‐α,	   was	   protective	   from	  obesity-­‐induced	   insulin	   resistance	   [Hotamisligil,	   1994].	   In	   addition,	   IL-­‐6,	   MCP-­‐1	   and	   TNF-­‐α	  seem	   to	   correlate	   to	   body	   weight	   and	   they	   have	   all	   been	   shown	   to	   link	   obesity	   to	   insulin	  resistance	  [Di	  Gregorio,	  2005].	  So,	  TRAIL	  treatment	  reduced	  significantly	   the	   fat	  mass	  of	   the	  mice	  by	  inducing	  apoptosis	  and/or	  affecting	  adipocytes	  differentiation.	  This	  might	  have	  in	  turn	  led	   to	   a	   significant	   reduction	   of	   circulating	   and	   hepatic	   IL-­‐	   6,	   as	   well	   as	   to	   a	   significant	  downregulation	  of	  MCP-­‐1	  and	  TNF-­‐α	   in	   the	   adipose	   tissue	  and	  TNF-­‐α	   in	   the	   skeletal	  muscle,	  possibly	   explaining	   its	   positive	  metabolic	   effects.	   However,	   we	   cannot	   exclude	   a	   direct	   anti-­‐inflammtory	   effect	   of	   TRAIL,	   which	   could	   have	   contributed	   to	   the	   amelioration	   of	   T2DM	  metabolic	  disturbances,	  as	  previous	  works	  have	  clearly	  demonstrated	  that	  TRAIL	  induces	  the	  apoptosis	  of	  activated	  macrophages	  and	  T	  cells	  in	  different	  tissues.	  Further	  studies	  are	  needed	  to	  clarify	  this	  issue.	  	  In	  conclusion,	  consistent	  with	  what	  has	  been	  previously	  reported,	  this	  work	  sheds	  light	  on	   the	   possible	   anti-­‐adipogenic	   and	   anti-­‐inflammatory	   effects	   of	   TRAIL	   and	   opens	   new	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therapeutic	   possibilities	   [Thomas,	   2012]	   against	  weight	   gain,	   systemic	   inflammation,	   insulin	  resistance	  and	  T2DM.	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